



5th
Edition

Solved Papers **PEDIATRICS** *for PG Students*

**A Must for MD and DNB Pediatrics, DCH, CPS
and Other Examinations Across India**

**Recommended by the Gold Medalists of various Universities (Gorakhpur,
Gujarat, Karnataka, Madhya Pradesh, Puducherry, Rajasthan, West Bengal, etc.)**

Ankit Yadavendra

Foreword
Prem Sheth



Contents

Basic Sciences of Anatomy, Physiology Related to Genetics—I

MD Summer 2024

1

1. LAQ: Describe sodium metabolism. Describe the etiology, clinical features and management of syndrome of inappropriate anti-diuretic hormone secretion (SIADH)..... 1
2. LAQ: Describe the inheritance pattern, clinical manifestations and management of thalassemia major2
3. SAQ: (any five out of six)
 - a. Assessment of growth in infancy6
 - b. Mitochondrial inheritance7
 - c. Marfan's syndrome7
 - d. Pulmonary sequestration.....8
 - e. Role of water soluble vitamins in treatment of childhood diseases.....9
 - f. Fluorescence in situ hybridization (FISH)9

DCH Summer 2024

10

1. LAQ: Define glomerular filtration rate (GFR). Explain the mechanisms regulating GFR and factors influencing its maintenance. Explore the dynamic changes in GFR across various age groups and elucidate the physiological adaptations. Finally discuss the various intrinsic and extrinsic factors which affect the GFR and its clinical implications..... 10
2. LAQ: Describe the transmission of impulses across the neurosynaptic cleft with a clear diagram. Discuss auto-immune myasthenia gravis versus congenital myasthenia syndromes. Elaborate upon the clinical features in both and investigations used. How will you treat a patient of myasthenia gravis? 11
3. SAQ: (any five out of six)
 - a. Obesity in children. Elaborate upon the causes, and approach to such a child..... 13
 - b. What are infantile hemangiomas? How are they classified? What the clinical "red flags" associated with Hemangiomas? 13
 - c. What are the genetic tests available to the clinician?..... 13
 - d. What are the differentials for congenital cataract in a child?..... 14
 - e. What is an autoantibody? In a tabular form enlist the typically seen autoantibodies associated with SLE and also elaborate on their clinical association. Which drugs are known to cause drug induced lupus? 15
 - f. What are the methods used to assess fetal growth and maturity? What are the clinical implications of this assessment? 16

DCH Winter 2023

17

1. LAQ: Describe pathophysiology of hyponatremia. Enumerate causes and treatment of hyponatremia..... 17
2. LAQ: Describe fetal circulation. Describe management of persistent pulmonary hypertension of neonate..... 17
3. SAQ: (any five out of six)
 - a. Cardiac death 17
 - b. Klinefelter syndrome 18
 - c. Hyperkalemia 19
 - d. Phenylketonuria 19
 - e. Homeless children 19
 - f. Autosomal recessive inheritance 20

MD Summer 2023**21**

1. LAQ: Discuss the development of trachea and esophagus. Classify Tracheo-Oesophageal fistula and discuss its clinical features and management and complications 21
2. LAQ: What are different modes of inheritance? Describe etiology, clinical features of Down's syndrome. How will you counsel the family of a child with Down's syndrome? 23
3. SAQ: (any five out of six)
 - a. Zinc therapy 23
 - b. Lactation failure 23
 - c. Enuresis and its management 23
 - d. Chorionic villous biopsy 23
 - e. Psychological problems in adolescence 23
 - f. Burns in children 23

MD Winter 2022**25**

1. LAQ: Define the term "intellectual disability". Describe the etiology, epidemiology, clinical manifestations, evaluation and management of a child with intellectual disability 25
2. LAQ: Define the term "Severe Acute Malnutrition (SAM)". Describe the etiopathogenesis, clinical manifestations, investigations, management, complications and prevention of SAM 28
3. SAQ: (any five out of six)
 - a. Hypernatremic dehydration 32
 - b. High frequency ventilation 32
 - c. Prenatal diagnosis of Wilson disease 32
 - d. Enuresis (Bed-Wetting) 33
 - e. Rational drug use in pediatric practice 33
 - f. Describe health supervision for children with Down's syndrome 33

MD Summer 2022**34**

1. LAQ: Enumerate the autosomal dominant categories of disorders in children. Describe clinical features and management of congenital adrenal hyperplasia 34
2. LAQ: Describe the physiology and mechanism of formation of cerebrospinal fluid. Enumerate the causes of raised intracranial pressures and its management 36
3. SAQ: (any five out of six)
 - a. Pathophysiology of edema in nephrotic syndrome 36
 - b. Development of testes 36
 - c. Genetics of Edwards syndrome 40
 - d. Recurrent abdominal pain in childhood 40
 - e. Hypothyroidism 40
 - f. Cardiac cycle 40

DCH Summer 2022**42**

1. LAQ: Define the term "poor scholastic performance (PSP)". Enumerate the causes of PSP in a 9-year-old child. Describe the approach to diagnosis, investigations, management and prevention of PSP 42
2. LAQ: Define the term "shock". Describe the etiopathogenesis, clinical manifestations, investigations, management and prognosis of septic shock in children 42
3. SAQ: (any five out of six)
 - a. Kerosene poisoning 44
 - b. Glasgow Coma Scale (GCS) 45
 - c. Autosomal recessive inheritance 45
 - d. Craniosynostosis 45
 - e. Cleft lip and palate 46
 - f. Management and prevention of lactational failure 47

MD Summer 2021**48**

1. LAQ: Explain the physiology of regulation of osmolality of plasma. Describe the etiology, clinical features and management of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH)..... 48
2. LAQ: Describe the morphogenesis of the liver and biliary system. Evaluate the utility of various investigations used for differentiating between neonatal hepatitis and biliary atresia 49
3. SAQ: (any five out of six)
 - a. Describe the clinical features and management of Fragile X syndrome 49
 - b. Genetic counseling..... 49
 - c. Hyperkalemia: Enumerate the causes and describe the management 49
 - d. Laboratory diagnosis of homocystinuria (homocystinemia)..... 49
 - e. Describe the role of zinc in health and disease..... 50
 - f. Peak expiratory flow monitoring..... 50

DCH Summer 2021**52**

1. LAQ: Describe the development of gastrointestinal tract. Discuss clinical features and management of infantile hypertrophic pyloric stenosis..... 52
2. LAQ: Discuss CSF circulation. Describe types, clinical features and management of various types of hydrocephalus in children 53
3. SAQ: (any five out of six)
 - a. Karyotyping 53
 - b. Anion gap 54
 - c. Physiology of thermoregulation in newborn 54
 - d. Trisomy 21..... 55
 - e. Vitamin D 55
 - f. Physiological changes in adolescence 55

MD Summer 2020**57**

1. LAQ: Describe the development of fetal heart in details. Describe the transition from fetal to neonatal circulation. Add note on interventional cardiac catheterization 57
2. LAQ: Discuss the physiology of hemostasis. Discuss the evaluation of child with bleeding/coagulation disorder 59
3. SAQ: (any five out of six)
 - a. Gene therapy 59
 - b. Hypokalemia..... 61
 - c. Neural tube defect..... 62
 - d. Clinical assessment of acid–base disorders..... 65
 - e. Progeria 66
 - f. Leukopenia..... 68

DCH Summer 2020**70**

1. LAQ: Describe the synthesis and physiological actions of thyroxine. Describe the clinical manifestations and management of congenital hypothyroidism..... 70
2. LAQ: Describe normal development of RBC. Discuss clinical features and management of sickle cell disease. Add a note on its genetic inheritance 71
3. SAQ: (any five out of six)
 - a. Autosomal recessive inheritance 74
 - b. Etiology and management of hyperkalemia 75
 - c. Monitoring the head circumference..... 77
 - d. Bronchogenic cyst: Origin, clinical manifestations and management..... 78
 - e. Vitamin C in health and disease..... 79
 - f. Clinical manifestations and diagnosis of Klinefelter syndrome 79

MD Winter 2019**81**

1. LAQ: Describe development of gut. Discuss clinical features and management of various developmental disorders in newborn including malrotation of gut 81
2. LAQ: Describe the physiology of puberty. Define the term precocious puberty. Enumerate the conditions and approach to diagnosis, investigations and management in a girl with precocious puberty 81
3. SAQ: (any five out of six)
 - a. Genetic counseling..... 81
 - b. Anion gap 83
 - c. Attention-deficit/hyperactivity disorder (ADHD) 84
 - d. Pulmonary function tests..... 86
 - e. Transition from fetal circulation to neonatal circulation 88
 - f. Physiological anemia of infancy 88

DCH Winter 2019**90**

1. LAQ: Describe development of heart. Discuss types of congenital heart diseases 90
2. LAQ: Describe development of hepatobiliary system. Discuss differential diagnosis of jaundice in 1 month old baby 90
3. SAQ: (any five out of six)
 - a. Genetics of Down's syndrome..... 90
 - b. Hypokalemia..... 90
 - c. Autosomal recessive disorders..... 90
 - d. Kangaroo mother care 91
 - e. Metabolic acidosis 91
 - f. Genetic counseling..... 92

MD Summer 2019**93**

1. LAQ: Describe the fetal circulation. Discuss the changes in circulation at birth. Outline approach to cyanosis in newborn baby 93
2. LAQ: Describe clinical features, cytogenetics, antenatal diagnosis and management of trisomy 21 94
3. SAQ: (any five out of six)
 - a. Karyotyping 96
 - b. Liver function test 98
 - c. Sexual maturity rating in children 98
 - d. Fragile "X" syndrome 98
 - e. Neural tube defect..... 100
 - f. Anion gap 100

DCH Summer 2019**101**

1. LAQ: Describe the synthesis and physiological actions of thyroxine (T4). Describe the clinical manifestations and management of congenital hypothyroidism 101
2. LAQ: Describe the development of liver and hepatobiliary system. Discuss clinical features and management of biliary atresia 101
3. SAQ: (any five out of six)
 - a. Management of hyperkalemia..... 101
 - b. Facility-based dietary management of a child with severe acute malnutrition (SAM)..... 102
 - c. Gene therapy 102
 - d. Role of zinc in health and disease 102
 - e. Turner syndrome..... 102
 - f. Management of nutritional rickets..... 102

MD Winter 2018**103**

1. LAQ: Describe the fetal development, physiology of thyroid. Discuss etiologic classification and management of congenital hypothyroidism..... 103
2. LAQ: Describe “tyrosine” metabolism. Discuss management of phenylketonuria in children..... 105
3. SAQ: (any five out of six)
 - a. Learning disability 105
 - b. Anion gap 105
 - c. Peripheral blood smear examination 105
 - d. Disseminated intravascular coagulation 107
 - e. Phototherapy..... 108
 - f. Pica..... 109

MD Summer 2018**110**

1. LAQ: Describe the development of liver. Describe bilirubin metabolism and discuss approach to a 2-month-old infant with cholestasis 110
2. LAQ: Enumerate common poisonings in children. Discuss pathophysiology, clinical features, and management of a child with paracetamol overdose 116
3. SAQ: (any five out of six)
 - a. Brain death 119
 - b. Epigenetics..... 122
 - c. Hypokalemia..... 124
 - d. Neurocutaneous markers..... 124
 - e. Growth velocity curve 126
 - f. Strategies to reduce infant mortality rate (IMR) 130

DCH Summer 2018**132**

1. LAQ: Describe CSF circulation. Discuss etiologies, clinical features, diagnosis and management of congenital hydrocephalus 132
2. LAQ: Describe the pattern of inheritance of genetic diseases. Discuss multifactorial inheritance. Add a note on antenatal diagnosis..... 134
3. SAQ: (any five out of six)
 - a. Oto-acoustic emission..... 137
 - b. Changes in foetal circulation at birth 138
 - c. X-linked recessive disorders 139
 - d. Patent foramen ovale 140
 - e. Malrotation of gut..... 142
 - f. Hyponatremia 145

MD Summer 2017**147**

1. LAQ: Describe the role of kidney in the maintenance of acid-base balance. Describe the clinical features and management of Renal Tubular Acidosis (RTA) 147
2. LAQ: Describe the physiology of lactation and composition of breastmilk. Explain the physiological basis and justification for feeding practices such as avoidance of pre-lacteal feeds, demand feeding, night feeding, exclusive breast-feeding, and rooming in 150
3. SAQ: (any five out of six)
 - a. Chelation therapy in thalassemia major 155
 - b. Fluorescent in situ hybridization (FISH) 155
 - c. Phenylketonuria 157
 - d. Mitochondrial inheritance 158
 - e. Thyroid Function Tests 160
 - f. Optimal health supervision for children with Down Syndrome..... 161

MD Summer 2016**162**

1. LAQ: Enumerate "Neural Tube Defects". Describe its prevention, clinical features, investigation, and management of lumbosacral meningocele..... 162
2. LAQ: Describe functions of platelets. Describe clinical features, investigations and management of idiopathic thrombocytopenic purpura (ITP) 162
3. SAQ: (any five out of six)
 - a. Trisomy 18..... 165
 - b. Magnesium deficiency in children..... 167
 - c. Hazards of toys in children 169
 - d. Bowlegs 170
 - e. Side effects of ART (Antiretroviral therapy) 172
 - f. Hypernatremic dehydration 175

DCH Summer 2016**177**

1. LAQ: Describe development of interventricular septum. Describe clinical features, investigations and management of a case of VSD..... 177
2. LAQ: Describe the SMR rating in a 12 years old boy. Discuss problems of adolescents..... 181
3. SAQ: (any five out of six)
 - a. Autosomal recessive disorders..... 183
 - b. Microcephaly 183
 - c. Modified Glasgow Coma Scale 184
 - d. Hypocalcemia..... 185
 - e. Development of kidneys 187
 - f. Vitamin A toxicity..... 190

MD Winter 2015**192**

1. LAQ: Enumerate the causes of immunodeficiency in childhood. Describe the clinical features and diagnostic approach of a child with suspected immunodeficiency 192
2. LAQ: What is epigenetics? Describe the mechanism and clinical implications of epigenetics 195
3. SAQ: (any five out of six)
 - a. Hypernatremic dehydration 195
 - b. Hypophosphatemic rickets 196
 - c. Infant of diabetic mother..... 198
 - d. Immunization in adolescence 201
 - e. Genetics of Down syndrome and its clinical implications 202
 - f. Development of lungs 203

MD Summer 2015**207**

1. LAQ: Describe development of foetal urinary tract. Enumerate congenital anomalies of urinary tract. Describe clinical features, investigations and management of posterior urethral valves..... 207
2. LAQ: Describe the physiology of puberty. Enumerate the conditions causing precocious puberty. Outline clinical manifestation laboratory finding and treatment of precocious puberty..... 212
3. SAQ: (any five out of six)
 - a. Stem cell transplant 212
 - b. Neural tube defect..... 214
 - c. Genetic counseling..... 214
 - d. Fragile X syndrome..... 214
 - e. Anion gap 214
 - f. Hypokalemia..... 214

DCH Winter 2014**215**

1. LAQ: Describe physiology of puberty and discuss approach and management of a 7 years old child presenting with precocious puberty 215
2. LAQ: Describe the physiology of urine formation and discuss the metabolic function of kidney..... 220
3. SAQ: (any five out of six)
 - a. SIADH (Syndrome of inappropriate secretion of ADH) 226
 - b. Aerosol therapy in asthma..... 228
 - c. Approach to diagnosis of a 1 months old infant born to HIV positive mother 230
 - d. Tools of assessment of growth and development at various ages 232
 - e. Turner syndrome..... 235
 - f. Midazolam..... 237

MD Summer 2014**239**

1. LAQ: Describe cerebrospinal fluid circulation. Describe clinical features investigation management and complications of hydrocephalus in a 2 years old child..... 239
2. LAQ: Describe mechanism of coagulation of blood, clinical features and management of von Willebrand disease 241
3. SAQ: (any five out of six)
 - a. Trisomy 21..... 244
 - b. Zinc in therapy 244
 - c. Management of Nuclear radiation injury..... 246
 - d. Gene therapy 247
 - e. Adverse effects of antitubercular drugs 247
 - f. Oral rehydration solution..... 249

Solved Paper—I 1–16 Questions**251**

1. Metabolic alkalosis 251
2. Vitamin E 253
3. G6PD deficiency 254
4. Antidiuretic hormone 256
5. Hypoglycemia 258
6. Micronutrients..... 260
7. Myasthenia gravis 262
8. Patau syndrome..... 264
9. Clinical manifestations, diagnosis (including differential diagnosis) and management of hypervitaminosis D..... 265
10. Prader Willi syndrome..... 266
11. Development of pancreas..... 267
12. Describe the embryonic development of placenta..... 270
13. Genetics and congenital heart diseases 271
14. Hypospadias 272
15. Development of nervous system 274
16. Leukocyte adhesion deficiency 276

Neonatology, Social Sciences Related to Paediatrics—II**MD Summer 2024****278**

1. LAQ: Enumerate major causes of neonatal mortality in India. Describe various strategies for achieving reduction in the neonatal deaths in India 278
2. LAQ: Describe the pathophysiology, prevention, clinical features and management of Hyaline Membrane Disease (HMD)..... 281

3. SAQ: (any five out of six)
 - a. Describe pre-natal diagnosis of Down syndrome.....281
 - b. Write a note on parental permission for performing a diagnostic procedure in a newborn baby.....281
 - c. Describe the risk factors for Autism Spectrum Disorders (ASD)281
 - d. Prevention of Necrotizing enterocolitis (NEC).....281
 - e. Social Phobia (Social anxiety disorder)281
 - f. Diagnosis of congenital syphilis282

DCH Summer 2024**283**

1. LAQ: Describe the etiopathogenesis, clinical manifestations, diagnosis, treatment, prognosis and prevention of neonatal necrotizing enterocolitis.....283
2. LAQ: Describe the pathophysiology, clinical manifestations, treatment, complications and prognosis of infants of diabetic mothers283
3. SAQ: (any five out of six)
 - a. Meconium aspiration syndrome283
 - b. Clinical manifestation and management of scurvy.....284
 - c. Congenital rubella syndrome.....285
 - d. Japanese encephalitis285
 - e. Accredited Social Health Activist (ASHA)287
 - f. Pediatric palliative care.....288

DCH Winter 2023**289**

1. LAQ: Describe the clinical manifestations, prevention and management of meconium aspiration syndrome in a new-born baby.....289
2. LAQ: A four-day old new-born baby is noted to have pathological indirect hyperbilirubinemia. Describe the diagnostic evaluation that assists in the determination of cause of indirect hyperbilirubinemia291
3. SAQ: (any five out of six)
 - a. Apnea of prematurity291
 - b. Role of pediatrician in adoption291
 - c. Temper tantrums.....291
 - d. Management of hypoglycemia in the new-born292
 - e. Hemorrhagic Disease of the New-born292
 - f. Bullying.....292

MD Summer 2023**293**

1. LAQ: Enumerate causes of respiratory distress in a newborn baby. Describe clinical features, investigations and management of persistent pulmonary hypertension in a neonate293
2. LAQ: Enumerate causes of child abuse. Describe investigations, prevention and management of child abuse in a one and half year old child293
3. SAQ: (any five out of six)
 - a. Prevention of birth asphyxia.....293
 - b. Hospital waste management system294
 - c. Psychological problems in an adolescent girl child294
 - d. Child adoption294
 - e. Prevention of sepsis in neonatal intensive care unit (NICU).....294
 - f. Congenital hypothyroidism294

MD Winter 2022**295**

1. LAQ: Define the term 'hypoxic-ischemic encephalopathy' in a neonate. Describe the etiology, pathophysiology, clinical manifestations, diagnosis, treatment and prognosis of neonatal hypoxic-ischemic encephalopathy.....295

2. LAQ: Describe the etiology, clinical manifestations, laboratory findings, differential diagnosis, treatment and prevention of iron-deficiency anemia in children.....	295
3. SAQ: (any five out of six)	
a. Specific learning disabilities.....	298
b. Immunizations in an adolescent	298
c. Prevention and management of lactation failure.....	298
d. Rashtriya Bal Swasthya Karyakram (RBSK)	298
e. Adoption rules and regulations in India	298
f. TORCH infections in Newborn.....	298

DCH Winter 2022**301**

1. LAQ: Describe the pathophysiology of birth asphyxia. Discuss the management of a extremely preterm neonate measuring 900 g, who is asphyxiated at birth	301
2. LAQ: Discuss distinguishing features of facility based integrated management of neonatal and childhood illnesses (F-IMNCI), discuss approach to management of a child presented with fever as per F-IMNCI guidelines	301
3. SAQ: (any five out of six)	
a. Kangaroo mother care (KMC)	302
b. Bullous eruptions in newborn.....	303
c. Antenatally detected hydronephrosis management	304
d. Adolescent's health problems.....	305
e. Nutritional recovery syndrome	305
f. Outline setting up of a NICU in a district hospital.....	306

MD Summer 2022**308**

1. LAQ: Enumerate the etiology, clinical features, investigations and management of Birth asphyxia in a neonate.....	308
2. LAQ: Discuss differential diagnosis and management of respiratory distress in newborn.....	308
3. SAQ: (any five out of six)	
a. Health consequences of childhood obesity.....	308
b. Fire accidents in Neonatal Nursery.....	309
c. Laboratory evaluation of a baby with polycythemia.....	311
d. Persistent pulmonary hypertension in Neonate	311
e. Reflexes involved in Lactation.....	311
f. Baby friendly hospital.....	311

MD Summer 2021**312**

1. LAQ: Define the term "premature birth". Describe the incidence, aetiopathogenesis, clinical assessment, management, complications and sequelae in a preterm baby	312
2. LAQ: Define the terms "child abuse" and "child neglect". Describe the various types of child abuse and neglect, its etiopathogenesis, clinical manifestations, investigations, management and prevention	315
3. SAQ: (any five out of six)	
a. Neonatal thrombocytopenia	318
b. Right to Education Act (RTE).....	319
c. Twin delivery.....	321
d. Congenital diaphragmatic hernia.....	322
e. Principles for the prevention of nosocomial infection in the neonatal intensive care unit (NICU)	322
f. Varicella during neonatal period.....	322

DCH Summer 2021**325**

1. LAQ: Enumerate causes of respiratory distress in a newborn baby. Discuss clinical features and management of hyaline membrane disease 325
2. LAQ: Describe clinical features, investigations, management and prevention of Necrotising Enterocolitis in newborn 325
3. SAQ: (any five out of six)
 - a. Umbilical cord examination 325
 - b. Low milk production 326
 - c. Retinopathy of prematurity 329
 - d. Infant mortality rate 329
 - e. School health program 330
 - f. Baby friendly hospital initiative 331

MD Summer 2020**332**

1. LAQ: Discuss the pathophysiology, clinical features and management of periventricular and intraventricular hemorrhage in preterm newborns 332
2. LAQ: Discuss Integrated Management of Neonatal and Childhood Illness (IMNCI) 334
3. SAQ: (any five out of six)
 - a. PPTCT 336
 - b. Management of a bleeding neonate 338
 - c. Nonimmune hydrops fetalis 340
 - d. Complications of ventilatory support in a newborn 341
 - e. Nocturnal enuresis 342
 - f. Neonatal seizures 343

DCH Summer 2020**344**

1. LAQ: Describe clinical features, investigations, management and complications in a newborn with early onset sepsis 344
2. LAQ: Outline the components of ICDS programme. Briefly discuss its impact on child health in India. Add a short note on causes for its failure 344
3. SAQ: (any five out of six)
 - a. Phototherapy 345
 - b. Prevention of hypothermia in a newborn 346
 - c. Current status of polio eradication 346
 - d. Rashtriya Bal Swasthya Karyakram (RBSK) 346
 - e. Human Milk Bank 346
 - f. Clinical features and management of hypoglycaemia in a newborn 346

MD Winter 2019**347**

1. LAQ: Describe in details etiology, clinical features and management of hypoglycemia in neonate. Add a note on persistent hypoglycemia in infant 347
2. LAQ: Describe etiology, pathogenesis, clinical features, diagnosis and treatment of dyslexia 347
3. SAQ: (any five out of six)
 - a. Hematuria in newborn 349
 - b. Baby friendly hospital 350
 - c. Kangaroo mother care 350
 - d. Child sexual abuse 351
 - e. Encopresis 354
 - f. Mechanical ventilation in respiratory distress syndrome 355

DCH Winter 2019**356**

1. LAQ: Discuss etiology, pathophysiology, clinical features and management of persistent pulmonary hypertension in the newborn..... 356
2. LAQ: Describe the psychosocial problems in adolescence and their management 358
3. SAQ: (any five out of six)
 - a. Learning disabilities 358
 - b. Child abuse..... 359
 - c. Management of bleeding in neonate 359
 - d. Neonatal seizures..... 359
 - e. Prevention of hospital-acquired infections 359
 - f. Mid-day school meal program..... 360

MD Summer 2019**361**

1. LAQ: A full term neonate develops the convulsion on day two of life. Enumerate the possible etiologies and discuss the management of neonatal seizures 361
2. LAQ: Enumerate causes of bleeding in newborn. Describe clinical features and management of haemorrhagic disease of newborn. Add a short note on its prevention..... 365
3. SAQ: (any five out of six)
 - a. Role of pediatrician in adoption 367
 - b. Child Physical Abuse..... 368
 - c. Surfactant Therapy..... 368
 - d. National Child Health Policies 368
 - e. IMNCI (Integrated Management of Neonatal and Childhood Illness) 369
 - f. Effect of maternal medication on fetus 369

DCH Summer 2019**371**

1. LAQ: Define hypoglycemia in the newborn. Enumerate the causes and describe the management of hypoglycemia in the neonatal period 371
2. LAQ: Enumerate causes of respiratory distress. Describe the etiology, clinical manifestations, prevention and management of hyaline membrane disease (HMD) 371
3. SAQ: (any five out of six)
 - a. Preadoption assessment of a child..... 371
 - b. Assessment of gestational age at birth..... 371
 - c. Prevention of hospital-acquired infection in the Neonatal Intensive Care Unit (NICU) 372
 - d. Kangaroo Mother Care (KMC)..... 372
 - e. Phototherapy..... 372
 - f. Nonaccidental injuries in children 372

MD Winter 2018**373**

1. LAQ: Describe development of foregut. Discuss management of a 2-day-old neonate presenting with vomiting and abdominal distension..... 373
2. LAQ: A 7-year-old presents with scholastic backwardness. Discuss approach and management..... 376
3. SAQ: (any five out of six)
 - a. Dog bite..... 376
 - b. Combination vaccines..... 378
 - c. Human Milk Bank..... 379
 - d. Palliative care in children..... 380
 - e. Adolescent psychiatric disorders 380
 - f. Management of obesity 382

MD Summer 2018	385
1. LAQ: Discuss common learning problems in school children	385
2. LAQ: Discuss clinical approach and management of neonatal seizures.....	389
3. SAQ: (any five out of six)	
a. Neonatal metabolic screening	389
b. Assessment of fetal well-being	391
c. Prevention of birth asphyxia.....	394
d. Retinopathy of prematurity.....	395
e. Child sexual abuse.....	399
f. Autism.....	399
DCH Summer 2018	403
1. LAQ: Describe etiology of jaundice in a newborn child. Describe approach to diagnosis of neonatal jaundice and its management.....	403
2. LAQ: Enumerate risk factors for neonatal sepsis. Describe clinical features, investigations and management of neonatal sepsis	407
3. SAQ: (any five out of six)	
a. Hemorrhagic disease of the newborn.....	410
b. Infant of diabetic mother.....	410
c. Role of pediatrician in child adoption.....	410
d. Ready-to-use therapeutic food (RUTF).....	410
e. Play therapy	411
f. Advantages of breastfeeding	413
MD Summer 2017	415
1. LAQ: Pathophysiology of hyaline membrane disease. Discuss prevention and management of hyaline membrane disease.....	415
2. LAQ: Describe learning disabilities in children. Discuss approach to a child with scholastic backwardness	418
3. SAQ: (any five out of six)	
a. RBSK: Child health screening and early intervention services	418
b. Biomedical waste management.....	421
c. Congenital diaphragmatic hernia.....	423
d. Feeding low birth weight babies	425
e. Osteopenia of prematurity.....	425
f. Use of CPAP in NICU	427
MD Summer 2016	429
1. LAQ: Describe the pathophysiology, clinical features, prevention and management of necrotizing enterocolitis (NEC) in newborn babies.....	429
2. LAQ: A twenty-day old infant is found to have jaundice. Enumerate the causes and describe the evaluation undertaken to determine the cause of jaundice	431
3. SAQ: (any five out of six)	
a. Strategies for preventing nosocomial infections in the Neonatal Intensive Care Unit (NICU).....	432
b. Mass newborn screening.....	434
c. Effects of maternal medications on the fetus.....	434
d. Prevention and management of Child Sexual Abuse: Role of a pediatrician.....	435
e. Substance Abuse in Adolescence	435
f. Healthcare delivery to children of migrant workers.....	438

DCH Summer 2016 **440**

1. LAQ: Describe the etiology, classification and management of neonatal seizures 440
2. LAQ: Describe the assessment of gestational age at birth and problems of Low Birth Weight (LBW) babies on the first day of life 440
3. SAQ: (any five out of six)
 - a. Role of a Pediatrician in the prevention of injuries in children 443
 - b. Phototherapy 444
 - c. Polycythemia in the newborn 444
 - d. Nocturnal enuresis 445
 - e. Problems of adolescent pregnancies 446
 - f. Congenital syphilis 447

MD Winter 2015 **449**

1. LAQ: Discuss etiology, clinical features, investigations and management of Hypertension in children 449
2. LAQ: Define Acute seizures. Discuss etiology and pathophysiology of acute seizures. Describe management of a child with status epilepticus 452
3. SAQ: (any five out of six)
 - a. Down syndrome 455
 - b. Ready to Use Therapeutic Food (RUTF) 455
 - c. Neonatal transport 455
 - d. Neurogenic bladder 457
 - e. Folic acid 460
 - f. Pertussis vaccine 462

MD Summer 2015 **465**

1. LAQ: Describe the etiology, pathophysiology, clinical manifestations and management of Hypoxic-Ischemic encephalopathy 465
2. LAQ: A six-day old baby is brought with the complaints of aversion to feeds and vomiting. Enumerate the possible causes and describe the approach to diagnosis 469
3. SAQ: (any five out of six)
 - a. Umbilical catheterization 471
 - b. Management of congenital diaphragmatic hernia in the neonatal period 472
 - c. Antibiotic policy for the Neonatal Intensive Care Unit (NICU) 472
 - d. Describe a pediatrician's role in the assessment and management of a child with suspected sexual abuse 474
 - e. Write a note on stuttering 474
 - f. Impact of television on children 476

MD Summer 2014 **478**

1. LAQ: What medical emergencies can you come across in the labour room in a neonate? How will you approach a case of neonatal anemia. Write in detail about etiopathogenesis, clinical features and treatment of Rh-incompatibilities 478
2. LAQ: Discuss the problems faced by children in a flood affected area. What is near drowning? Enumerate the rights of children 482
3. SAQ: (any five out of six)
 - a. Feeding in a premature baby 484
 - b. Hyponatremia 486
 - c. Immunization in immunocompromised 488
 - d. Neonatal resuscitation 490
 - e. Delayed puberty 493
 - f. Adoption 495

Solved Paper—II 1–41 Questions

498

1. Complementary feeding	499
2. Neonatal hypothermia.....	500
3. Child guidance clinic.....	502
4. Munchausen syndrome by proxy.....	503
5. Approach to common rashes in a newborn.....	505
6. Transient tachypnea of newborn	507
7. Hookworm infestation	508
8. Under five clinic	510
9. Kernicterus.....	510
10. Intrauterine growth restriction/retardation	513
11. Exchange transfusion	515
12. Human milk fortifier	516
13. Thermoneutral environment.....	517
14. Warm chain	518
15. OPV.....	519
16. BCG.....	520
17. Hepatitis B vaccine.....	521
18. Pneumococcal vaccine.....	521
19. Hib vaccine	522
20. Influenza vaccine.....	522
21. Ayushman Bharat Programme	523
22. Rashtriya Kishor Swasthya Karyakram.....	525
23. Kishori Shakti Yojana	526
24. ARSH Programme.....	527
25. Mother's Absolute Affection Programme.....	528
26. Anemia Mukht Bharat Programme.....	529
27. LaQshya Initiative.....	530
28. Open vial policy and Vaccine vial monitor	531
29. Yellow fever vaccine	532
30. Measles vaccine	532
31. Hepatitis A Vaccine	533
32. Varicella vaccine	533
33. Anorectal malformations	534
34. Pradhan Mantri Matru Vandana Yojana.....	536
35. Weaning from ventilator	537
36. Neonatal reflexes.....	537
37. Normal motor development in first year of life.....	539
38. Delivery room care of a normal newborn	540
39. Enterobius vermicularis infection	540
40. Newer Antimalarials	542
41. Lactose Intolerance	543

Systemic Diseases in Pediatrics: Respiratory, Cardiology, CVS, Neurology, Hematology, Nephrology, Rheumatology, Immunology, Metabolic, Gastroenterology, Growth and Development, Congenital and Acquired Disorders of Ear, Nose, Throat and Joints, Endocrine System, and Miscellaneous Diseases—III

MD Summer 2024

546

1. LAQ: Describe hemostatic mechanism. Discuss approach to management of a child, age 3 years, presented with petechiae over body..... 546
2. LAQ: 2-years-old child presented with progressive dyspnea and X-ray chest revealed mediastinal mass. Discuss differential diagnosis and approach to the management of this case..... 546
3. SAQ: (any five out of six)
 - a. Algorithmic approach to a 2 years old child with UTI..... 547
 - b. Cytokines in allergic disorders..... 548
 - c. Bone deformities in metabolic disorders..... 548
 - d. Infantile spasms..... 549
 - e. Anaphylactic reaction..... 549
 - f. Mushroom poisoning..... 550

DCH Summer 2024

552

1. LAQ: Define the term “fever of unknown origin” (FUO). Describe the approach to diagnosis, physical examination, investigations and management in a child with FUO..... 552
2. LAQ: Describe the pathogenesis, clinical manifestations, diagnosis, differential diagnosis and treatment of Wilson disease (hepatolenticular degeneration)..... 552
3. SAQ: (any five out of six)
 - a. Henoch-Schönlein purpura (HSP)..... 554
 - b. Hypertensive encephalopathy..... 554
 - c. Hypernatremic dehydration..... 555
 - d. Scrub typhus..... 555
 - e. Neurocysticercosis..... 556
 - f. Congenital hypothyroidism..... 556

DCH Winter 2023

557

1. LAQ: Describe the differential diagnosis of hypotonia in infancy..... 557
2. LAQ: Enumerate the causes of cyanosis in a four-year-old child. Describe the clinical manifestations, complications and management of a child with Tetralogy of Fallot..... 557
3. SAQ: (any five out of six)
 - a. Steroid resistant Nephrotic Syndrome..... 560
 - b. Management of allergic rhinitis..... 560
 - c. Typhoid vaccines..... 560
 - d. Oseltamivir..... 561
 - e. Management of Dengue Shock Syndrome..... 561
 - f. Prevention of mother-to-child transmission of HIV infection..... 561

MD Summer 2023

562

1. LAQ: Describe the pathophysiology and genetics of Hemophilia (Factor VIII or Factor IX or Factor XI deficiency). Describe the clinical manifestations, laboratory diagnosis, differential diagnosis, acute and chronic management and prevention of Hemophilia..... 562
2. LAQ: Enumerate the Neurocutaneous syndromes. Describe their clinical manifestations, diagnosis and management..... 565

3. SAQ: (any five out of six)
 - a. Kawasaki disease 566
 - b. Allergic rhinitis 567
 - c. Dengue shock syndrome 567
 - d. Gluten-sensitive enteropathy (Celiac disease) 567
 - e. Pulmonary arterial hypertension 567
 - f. Acute Disseminated Encephalomyelitis (ADEM) 568

MD Winter 2022**569**

1. LAQ: Enumerate the organisms causing bacterial meningitis in children. Describe pathophysiology, clinical features, diagnosis and management of meningoencephalitis in children 569
2. LAQ: Discuss hypertension in children. Discuss etiology, pathophysiology, clinical features and management of hypertension in children 570
3. SAQ: (any five out of six)
 - a. Clinical features and management of celiac disease 570
 - b. Management of episode of acute severe asthma in a 6 year old child 572
 - c. Approach to a 10 year old boy presenting with sudden onset of hematuria 572
 - d. Discuss etiology, clinical features and management of Encopresis 572
 - e. Principles of hospital management of severe acute malnutrition 572
 - f. Clinical features and management of atopic dermatitis 572

DCH Winter 2022**573**

1. LAQ: Write classification of haemolytic anaemias. Describe in detail clinical features, diagnosis and management of sickle cell anaemia. Add a note on HPLC in Haemoglobinopathies 573
2. LAQ: Discuss differential diagnosis of 5 year old baby resending with acute onset of altered sensorium. Describe in brief various modalities for treatment of raised intracranial tension. Add a note on management of neurotuberculosis 576
3. SAQ: (any five out of six)
 - a. Diagnostic approach to renal tubular acidosis 578
 - b. Management of tumour lysis syndrome 578
 - c. Discuss in brief approach to a 2 month old baby presenting with fever since 4 days without focus 578
 - d. Gastroesophageal reflux disease in infants: clinical features and management 578
 - e. Management of cyanotic spells 580
 - f. Clinical features and management of neonatal hypothyroidism 582

MD Summer 2022**583**

1. LAQ: What is SIRS (systemic inflammatory response syndrome)? Enumerate the causes. Discuss pathophysiology and management of Septic shock 583
2. LAQ: Discuss pathogenesis, clinical features, diagnosis and management of neurotuberculosis 583
3. SAQ: (any five out of six)
 - a. Demineralising bone diseases 584
 - b. Portal hypertension in sickle cell patient 584
 - c. Opportunistic infections in HIV infected children 584
 - d. Management of resistant malaria 584
 - e. Toxic epidermal necrolysis 584
 - f. Antiphospholipid syndrome 585

MD Summer 2021**587**

1. LAQ: One year old child is found to be severely pale with hepatosplenomegaly. Discuss differential diagnosis and management 587
2. LAQ: Discuss approach to a five year old child with cyanosis and clubbing 588

3. SAQ: (any five out of six)	
a. Lump in abdomen	588
b. Large head in a one year old child	590
c. Pleural effusion	591
d. West syndrome	592
e. Pancarditis	593
f. Inhalation therapy in asthma	593

DCH Summer 2021**594**

1. LAQ: Enumerate causes of pyrexia of unknown origin in children. Describe clinical features, investigations, complications and management of enteric fever. Add a note on its prevention	594
2. LAQ: Enumerate causes of shock in children. Discuss aetiology, pathophysiology and clinical features of cardiogenic shock. Add a note on management of cardiogenic shock	594
3. SAQ: (any five out of six)	
a. Cutaneous fungal infections	596
b. Differential diagnosis of floppy infant	597
c. Steroid resistant nephrotic syndrome	597
d. White patch on tonsils	597
e. Pediatric palliative care	598
f. Fate of primary complex	598

MD Summer 2020**600**

1. LAQ: A three-year old boy presents with chronic cough. Enumerate the possible causes and discuss the differential diagnosis and evaluation plan to determine the cause	600
2. LAQ: Enumerate the causes of chronic liver disease in children. Describe the clinical manifestations, diagnostic approach and management of a child liver disease	603
3. SAQ: (any five out of six)	
a. Management of Idiopathic (Autoimmune) thrombocytopenic purpura	603
b. Epilepsy surgery in children	603
c. Management of a child with tachyarrhythmia	604
d. Intussusception: Clinical Features and Management	604
e. Non invasive ventilation	606
f. Atopic Dermatitis	607

DCH Summer 2020**608**

1. LAQ: A 2 year old boy presents with chronic cough. Enumerate the possible causes. Describe the management of cystic fibrosis	608
2. LAQ: Discuss the diagnostic approach in a child with recurrent abdominal pain	611
3. SAQ: (any five out of six)	
a. Role of LFT's in evaluation of childhood disease	613
b. Vitamin D resistant Rickets	613
c. Hypokalemia	613
d. MAC-importance and drawbacks	613
e. DDH (Development Dysplasia of Hip)	614
f. Scabies	614

MD Winter 2019**616**

1. LAQ: Describe the clinical features, differential diagnosis and management of dengue infection in children	616
2. LAQ: Describe the etiology, differential diagnosis and management of recurrent fainting episodes in a seven-year-old-girl	616

3. SAQ (any five out of six):
 - a. Describe the clinical manifestations and management of Neuroblastoma 619
 - b. Randomization in Pediatric Clinical Trials..... 620
 - c. Investigations in prolonged infantile cholestasis..... 621
 - d. Rotavirus vaccine 621
 - e. Describe the diagnosis and Management of Steroid resistant Nephrotic Syndrome 621
 - f. Bronchial Asthma: Devices for the delivery of inhalational drugs 621

DCH Winter 2019

622

1. LAQ: Enumerate causes of proteinuria in children. Describe aetiopathogenesis, pathophysiology, clinical features and management of child with idiopathic nephrotic syndrome. Add a note on its complications..... 622
2. LAQ: Describe aetiology, pathophysiology, clinical features and management of 1-year-old child with acute bacterial meningitis 624
3. SAQ: (any five out of six)
 - a. Second line ART..... 626
 - b. Idiopathic thrombocytopenic purpura..... 627
 - c. Status Asthmaticus..... 627
 - d. CROUP Syndrome 629
 - e. Hydroxyurea therapy for Sickle Cell Disease..... 630
 - f. Juvenile hypothyroidism..... 631

MD Summer 2019

634

1. LAQ: Write approach to a child with polyarthritis. Write in detail about clinical features and management of systemic onset JRA. Add a note on macrophage activation syndrome..... 634
2. LAQ: Discuss approach to child with haematemesis. Write clinical features and management of extrahepatic portal hypertension. Add a note on liver transplantation 638
3. SAQ: (any five out of six)
 - a. Congenital dislocation of Hip..... 641
 - b. Management of tumour lysis syndrome 642
 - c. Recent advances in management of bronchiolitis 642
 - d. Treatment of intractable Congestive Cardiac Failure..... 642
 - e. Iron chelation therapy..... 642
 - f. Pseudohypoparathyroidism..... 642

DCH Summer 2019

643

1. LAQ: Enumerate causes of anemia in children. Discuss aetiopathogenesis, clinical features and management of acute autoimmune hemolytic anemia..... 643
2. LAQ: Discuss causes of Portal hypertension in children. What are its signs and symptoms? How will you diagnose and manage such a case? 645
3. SAQ: (any five out of six)
 - a. Haemolytic uraemic syndrome..... 648
 - b. Stevens-Johnson Syndrome 648
 - c. IPV vaccine..... 649
 - d. Complications of malaria 650
 - e. Vasculotoxic snake bite..... 651
 - f. Congenital dislocation of Hip..... 651

MD Winter 2018**652**

1. LAQ: Discuss approach to a child with upper airway obstruction 652
2. LAQ: Define febrile seizures in children. Discuss etiology, clinical features, investigations and management of a typical febrile seizures 655
3. SAQ: (any five out of six)
 - a. Methodology of blood collection for blood culture and interpretation of blood culture reports..... 658
 - b. Rubella vaccine 660
 - c. Ventricular septal defect 660
 - d. Dermatological manifestations in a child with immunodeficiency..... 663
 - e. Child adoption 664
 - f. Management of button battery ingestion..... 664

MD Summer 2018**666**

1. LAQ: Describe the etiology and pathogenesis of childhood asthma. Describe assessment of asthma severity and key elements of optimum out-patient management of childhood asthma..... 666
2. LAQ: Describe the etiopathogenesis, clinical features, diagnosis, management, complications and prevention of typhoid fever in children 667
3. SAQ: (any five out of six)
 - a. Acute febrile encephalopathy..... 670
 - b. Autoimmune hepatitis 674
 - c. Neurocysticercosis..... 676
 - d. Steroid resistance nephrotic syndrome..... 678
 - e. Drug therapy of congestive cardiac failure 680
 - f. Snake-bite poisoning 683

DCH Summer 2018**689**

1. LAQ: Classify congenital heart diseases. Write in details about types, clinical features, management of a child with interventricular septal defect. Add a note on the complications 689
2. LAQ: Enumerate causes of respiratory distress in newborn. Discuss clinical features and management of respiratory distress syndrome in newborn..... 690
3. SAQ: (any five out of six)
 - a. Febrile seizures 691
 - b. Bronchiolitis 691
 - c. Secondary Sexual Characters 694
 - d. Toxic shock syndrome 695
 - e. Opportunistic infections in HIV..... 696
 - f. Reye's syndrome 698

MD Summer 2017**700**

1. LAQ: Define pyrexia of unknown origin (PUO). Enumerate causes of PUO. Discuss approach to a 6-year-old child with PUO..... 700
2. LAQ: A 10-year-old child has come with focal convulsions for the first time. Discuss differential diagnosis and management of focal seizures in this child..... 703
3. SAQ: (any five out of six)
 - a. Therapeutic uses of vitamin C 705
 - b. SIDS 707
 - c. Pulmonary function tests..... 709
 - d. Precocious puberty 709
 - e. Pathophysiology and management of hemolytic uremic syndrome 709
 - f. Management of chronic renal failure 709

MD Summer 2016**712**

1. LAQ: Discuss the differential diagnosis and approach to management of a child presented with coarse facies 712
2. LAQ: Describe normal tubular functions of kidney and discuss approach to a child age 2 years and weight 10 kg with proximal tubular acidosis 714
3. SAQ: (any five out of six)
 - a. Stepwise therapy in a 3-year-old child weighs 10 kg presented with raised intracranial pressure 715
 - b. Hypernatremic dehydration 715
 - c. Genitourinary imaging techniques and their applications 715
 - d. Risk stratification in acute lymphoblastic leukemia 718
 - e. Approach to a child with recurrent pneumonia 719
 - f. Hepatic venous outflow obstruction 721

DCH Summer 2016**724**

1. LAQ: Enumerate the causes of cholestasis in an infant. Describe the clinical manifestations, approach to diagnosis and management of an infant presenting with cholestasis 724
2. LAQ: Enumerate the histologic types of idiopathic nephrotic syndrome. Describe the diagnosis, management and complications of nephrotic syndrome 727
3. SAQ: (any five out of six)
 - a. Diagnosis and management of acute rheumatic carditis 731
 - b. Congenital hypothyroidism 733
 - c. Acute Disseminated Encephalomyelitis (ADEM) 736
 - d. Status epilepticus 737
 - e. Clinical manifestations and management of Henoch–Schönlein purpura (HSP) 739
 - f. Attention Deficit Hyperactivity Disorder (ADHD) 740

MD Summer 2015**741**

1. LAQ: Describe clinical features, complications and management of acute viral myocarditis in a one year old child 741
2. LAQ: Discuss diagnostic approach in a child with resistant rickets 743
3. SAQ: (any five out of six)
 - a. Dyslexia 745
 - b. Subcutaneous vaccines 745
 - c. Osteogenesis imperfecta 747
 - d. Management of scorpion bite 749
 - e. Allergic rhinitis 750
 - f. Megaloblastic anemia 753

MD Winter 2014**756**

1. LAQ: Describe etiology, clinical features, investigations and management in a child with phenylketonuria 756
2. LAQ: Discuss causes and management of chronic liver disease 756
3. SAQ: (any five out of six)
 - a. Ventilator associated pneumonia 758
 - b. Vitamin D and management of Rickets 761
 - c. Causes of discoloured urine 763
 - d. Hypernatremic dehydration 763
 - e. Differential diagnosis of Acute flaccid paralysis 764
 - f. Fiberoptic bronchoscopy 766

MD Summer 2014**768**

1. LAQ: Discuss approach to a 5-year-old male child with recurrent wheezing. Write in details grades and management of bronchial asthma 768
2. LAQ: Define Diabetic ketoacidosis. Describe in details clinical features, diagnosis, management and complications of diabetic ketoacidosis 773
3. SAQ: (any five out of six)
 - a. Duchenne muscular dystrophy 776
 - b. Albright hereditary osteodystrophy 778
 - c. Role of zinc in pediatrics 779
 - d. Management of vesicoureteral reflux 779
 - e. Iron poisoning 781
 - f. Atopic dermatitis 782

Solved Paper—III 1–28 Questions**785**

1. Measles 786
2. Poliomyelitis 789
3. Cerebral palsy 793
4. Undescended testis 797
5. Urinary tract infection 800
6. Tic disorders 804
7. Breath holding spells 806
8. Guillain-Barré syndrome 808
9. Transverse myelitis 811
10. Dengue fever 812
11. Leptospirosis 817
12. Acute otitis media 819
13. Pediculosis 820
14. Leukemoid reaction 822
15. Non-Hodgkin's lymphoma 823
16. Zika virus 825
17. Nipah virus infection 826
18. Acute rheumatic fever 826
19. Cretinism 830
20. Congenital megacolon 831
21. Treatment of malaria 832
22. Sexual education in adolescents 834
23. Urticaria 835
24. Enumerate causes of hematuria in children. Discuss etiopathogenesis, clinical features, laboratory diagnosis and management of acute glomerulonephritis 837
25. Clubbing 839
26. Cyanosis 840
27. Viral hepatitis 841
28. Cerebrospinal fluid examination 841

Recent Advances in Pediatrics—IV**MD Summer 2024****843**

1. LAQ: Discuss the stepwise management of asthma in children. Mention the recent advances in use of inhaled corticosteroids in acute asthma exacerbations 843
2. LAQ: LAQ: Discuss the preparation of the patient for Hematopoietic stem cell transplantation in pediatrics. Discuss the procedure and the post transplant care in this patient 843

3. SAQ: (any five out of six)
 - a. Fluorescent In Situ Hybridization (FISH) 843
 - b. Describe the role of End Tidal Carbon dioxide (ETCO₂) monitoring in pediatric critical care 844
 - c. Describe the modalities of treatment of Patent Ductus Arteriosus in preterms 844
 - d. Discuss the Grading and management of vesico-ureteric reflux 844
 - e. Injectable Polio Vaccine (Sabin) 844
 - f. CB-NAAT (Cartridge Based Nucleic Acid Amplification test) in tuberculosis 844

MD Summer 2023**845**

1. LAQ: Describe the Consensus Guidelines for the management of Severe Acute Malnutrition (SAM) in Indian Children 845
2. LAQ: Define non-invasive ventilation. Describe the modes/techniques, mechanism of action, indications, contraindications and limitations of non-invasive ventilation in pediatrics 845
3. SAQ: (any five out of six)
 - a. Management of patent ductus arteriosus in pre-term babies 845
 - b. Pediatric Cochlear implantation: Indications, Constraints and Outcomes 846
 - c. Umbilical Cord Blood Bank 846
 - d. Sildenafil in the management of Pulmonary Hypertension 846
 - e. Use of Biologicals in the treatment of Juvenile Idiopathic Arthritis (JIA) 846
 - f. Strategies for Measles control in India 847

MD Winter 2022**848**

1. LAQ: Enumerate causes of CCF (congestive cardiac failure) in newborn. Describe clinical features, investigation, and management of cardiogenic shock in new born baby 848
2. LAQ: Enumerate Hemoglobinopathies. Describe clinical features, investigations, management and prevention of sickle cell disease 849
3. SAQ: (any five out of six)
 - a. Morphine 849
 - b. Complications of ventilator therapy 850
 - c. Rectal drug therapy 850
 - d. Newer antiepileptic drugs 851
 - e. Stem cell therapy 851
 - f. Combination vaccines 851

MD Summer 2022**852**

1. LAQ: Define Severe Acute Malnutrition (SAM). Enumerate the indications for admission of a child with SAM to a healthcare facility. Describe the in-hospital/facility-based care required to be provided to child with SAM. 852
2. LAQ: A five-year old child presents with third episode of pneumonia. Enumerate the possible causes and describe the differential diagnosis for repeated episodes of pneumonia 852
3. SAQ: (any five out of six)
 - a. Therapeutic uses of intravenous immunoglobulin (IVIG) in children 852
 - b. Rotavirus vaccine 853
 - c. Diagnosis of Drug-resistant tuberculosis in children 853
 - d. Enzyme replacement therapy for Gaucher's disease 853
 - e. Liver transplantation in children 854
 - f. Newborn Hearing Screening 855

MD Summer 2021**857**

1. LAQ: State recent guidelines on diagnosis and management of rheumatic carditis in children 857
2. LAQ: Describe etiology and current concepts about management of parapneumonic effusion in children 857

3. SAQ: (any five out of six)
 - a. Newer modalities of treatment of Retinopathy (ROP) of prematurity.....859
 - b. Human papilloma virus vaccine859
 - c. Enumerate the breast feeding indicators.....860
 - d. Hunger index.....860
 - e. Child death audit.....861
 - f. Hypotonia in an infant864

MD Summer 2020**866**

1. LAQ: Enumerate the autism spectrum disorders. Describe the clinical manifestations, diagnosis, differential diagnosis, epidemiology, treatment and prognosis of autistic disorder866
2. LAQ: Enumerate conditions associated with chronic hypertension in children. Describe the etiopathogenesis, clinical findings and manifestations, approach to diagnosis, treatment, complications and prevention of chronic hypertension in children.....866
3. SAQ: (any five out of six)
 - a. Anticoagulant and thrombolytic therapy in pediatric practice867
 - b. Refractory, incomplete and atypical Kawasaki disease.....868
 - c. H1N1 (Swine flu) infection in children.....869
 - d. Use of probiotics in children871
 - e. Autoimmune encephalitis in children.....871
 - f. Microarray and DNA sequencing for diagnosis872

MD Winter 2019**875**

1. LAQ: Define Prebiotics and probiotics. Explain their physiological mechanism of action. Describe the effects of probiotic in various gastro-intestinal disorders875
2. LAQ: Describe the methods for diagnosis of foetal disorders. Describe the foetal medical and surgical therapeutic options for various foetal disorders.....876
3. SAQ: (any five out of six)
 - a. Decision making for life sustaining therapies in paediatric intensive care.....877
 - b. Pentavalent vaccine and adverse events following immunization878
 - c. Impact of implementation of Navjat Shishu Suraksha Karyakram (NSSK) on Neonatal Mortality Rate (NMR) in Maharashtra.....879
 - d. Haemophagocytic Lymphohistiocytosis syndrome in Dengue hemorrhagic fever879
 - e. Polymerase chain reaction and its significance in clinical practice880
 - f. Comparison of high dose versus low dose aspirin in the management of Kawasaki disease.....881

MD Summer 2019**883**

1. LAQ: Discuss the conditions appropriate for pediatric palliative care. Describe recent guidelines and detail pharmacological approach for pediatric pain management883
2. LAQ: Discuss the rationale behind change of new American Heart Association guidelines 2010 for pediatric resuscitation. Describe the approach to a child presenting with supraventricular tachycardia with poor pulse. Add a note on automated external defibrillation.....886
3. SAQ: (any five out of six)
 - a. High frequency ventilation887
 - b. Recent management modalities and approach to fluid refractory septic shock888
 - c. Modalities for intrauterine diagnosis of fetal diseases.....889
 - d. Allergen Immunotherapy: Indications and contraindications for treatment of allergic disorders889
 - e. Newer approaches in management of Congestive Cardiac Failure in Children.....889
 - f. Umbilical cord blood banking for stem cell transplantation890

MD Winter 2018**893**

1. LAQ: Emergency medical services for children 893
2. LAQ: The genetic approach in pediatric medicine 895
3. SAQ: (any five out of six)
 - a. Therapeutic hypothermia 897
 - b. Stem cell therapy 900
 - c. Neurological complications of nutritional anemias 900
 - d. Levetiracetam 902
 - e. Hyperbaric O₂ therapy 903
 - f. Vitamin B₆ 904

MD Summer 2018**906**

1. LAQ: What is stem cell transplant? Discuss indications, availability and problems of stem cell transplantation in India 906
2. LAQ: A 3 years old child presents with recurrent wheezing. Discuss newer modalities of childhood asthma 906
3. SAQ: (any five out of six)
 - a. Newer antifungal drugs 909
 - b. Newer surfactant 911
 - c. Dengue vaccine 913
 - d. PMTCT (Prevention of Mother to Child Transmission) – newer concepts 915
 - e. Treatment of MDR TB 915
 - f. Ebola virus 915

MD Summer 2017**918**

1. LAQ: Enumerate risk factors for thrombosis in children. Describe clinical features, diagnosis, laboratory investigations, treatment and complications of thrombotic disorders in children 918
2. LAQ: Describe etiopathogenesis, clinical features, diagnosis and management of type 1 diabetes mellitus in children 920
3. SAQ: (any five out of six)
 - a. Biomarkers of acute kidney injury 923
 - b. Tumour lysis syndrome 924
 - c. Kawasaki disease 927
 - d. Donor human milk banking 929
 - e. Genexpert 931
 - f. Enzyme replacement therapy 933

MD Summer 2016**935**

1. LAQ: Describe the etiology, classification, pathophysiology, clinical manifestations, management and prognosis of Hemolytic Uremic Syndrome (HUS) 935
2. LAQ: Enumerate the causes and describe the pathophysiology, clinical features, monitoring, and management of raised intra-cranial pressure in children 938
3. SAQ: (any five out of six)
 - a. Umbilical cord blood transplantation 941
 - b. Japanese encephalitis vaccine 941
 - c. Therapeutic cooling for perinatal asphyxia 942
 - d. Pediatric cochlear implant 942
 - e. Pediatric Palliative Care Consultation 944
 - f. Immunosuppressive therapy 944

MD Winter 2015 946

1. LAQ: Describe in detail status of stem cell transplantation including indications, feasibility and problems.....946
2. LAQ: Describe newer vaccine. Discuss adverse events after vaccination and vaccines in special situations.....950
3. SAQ: (any five out of six)
 - a. Embolization as an intervention955
 - b. Carnitine therapy957
 - c. ECMO therapy959
 - d. Peri-implantation Genetic Diagnosis961
 - e. High dose sequential phenobarb therapy.....962
 - f. Evidence-based medicine.....963

MD Summer 2014 965

1. LAQ: Discuss in details, newer modalities of treatment and newer anticonvulsants in management of childhood seizures965
2. LAQ: Describe in details clinical manifestations, diagnosis, and management of supraventricular tachycardia in infant.....967
3. SAQ: (any five out of six)
 - a. Vasopressors in septic shock.....970
 - b. Genes involved in oncogenesis972
 - c. Management of multidrug resistant tuberculosis973
 - d. Vitamin D deficiency in childhood, current guidelines on diagnosis and management in brief976
 - e. Modes of alleviation of pain in neonates976
 - f. Neonatal resuscitation current guidelines.....978

Solved Paper—IV 1–10 Questions 979

1. Compulsive digital gaming979
2. National Nutrition Strategy981
3. Newer Strategies for Improving the Newborn Health in India.....984
4. Newer Drugs for Tuberculosis Prevention and Treatment in Children986
5. Nikshay Poshan Yojana.....988
6. Newer diagnostic tests in paediatric TB.....988
7. Telemedicine in pediatric practice.....992
8. Multiplex molecular assays for diagnosis of infectious agents994
9. Emergency Triage Assessment and Treatment (ETAT) Guidelines995
10. Apgar score998

Paper—I**DNB Pediatrics October 2023** 1001

- 1a. Infant mortality rate (IMR) and causes of infant mortality1001
- 1b. Sustainable development goals (SDGs).....1001
- 2a. Classification of cough or difficult breathing in a child age 2 months up to 5 years as per IMNCI.....1002
- 3b. WHO classification of dehydration.....1003
- 4a. Properties of Robust Quality Measures.....1003
- 4b. PRISM scoring system.....1003
- 5a. Religious or cultural objections to treatment.....1004
- 5b. Conditions appropriate for pediatric palliative care1004
- 6a. Risk factors for childhood injuries.....1004
- 6b. Bullying and cyberbullying1005

7a. Indications for STI screening in children with suspected sexual abuse	1006
7b. Fetal, transitional and neonatal circulation	1006
8a. ROC curve and AUC.....	1006
8b. Type 1 and Type 2 error in statistics.....	1007
9a. Normal and abnormal QRS complexes in ECG.....	1007
9b. Lab testing for diagnosis and classification of anemia.....	1008
10a. "Red Flags" in developmental screening and surveillance	1008
10b. Standardized tools for language and autism screening	1009

DNB Pediatrics April 2023

1010

1a. Describe embryonic development of heart	1010
1b. Enumerate various duct dependent congenital heart diseases that can present as neonatal emergencies	1010
2a. Describe principles of sedation in children undergoing day care procedures.....	1011
2b. Enumerate drugs commonly used for short term sedation in children	1011
3a. Describe regression analysis	1011
3b. Enumerate the composition of facility based newborn care.....	1012
4a. Nucleic Acid Amplification Tests (NAAT).....	1012
4b. Fixed Drugs Combination of antitubercular drugs under National Tuberculosis Elimination Programme	1013
5a. Describe the screening tests for IEM.....	1014
5b. Describe the investigations and treatment of nutritional rickets.....	1014
6a. Define the steps of randomized controlled trial.....	1014
6b. What is meta-analysis?	1015
7a. Outline the 10 steps of management of SAM as per WHO guidelines	1015
7b. Describe F-75 diet.....	1016
8a. Describe multiple inflammatory syndrome in children	1016
8b. Suman Health Program.....	1018
9a. Role of folate in body metabolism.....	1020
9b. Enumerate the clinical features, diagnosis and treatment of folate deficiency	1020
10a. What is MR campaign?	1020
10b. Difference between acellular and whole cell pertussis vaccine.....	1020

DNB Pediatrics June 2022

1021

1a. Describe/diagrammatic presentation of fetal circulation	1021
1b. Describe the management of primary pulmonary hypertension.....	1021
2a. Describe the bilirubin metabolism in neonates	1022
2b. Management approach in a baby with prolonged jaundice	1022
3a. Risk biases and confounding factors in a clinical study	1022
3b. Forest plot and its interpretation	1023
4a. Describe the types of clinical study designs	1024
4b. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to evaluate the level of evidence	1025
5a. Describe the development of diaphragm.....	1026
5b. Current recommendations for management of diaphragmatic hernia	1027
6a. Describe the iron metabolism in the human body.....	1027
6b. Management of hypochromic microcytic anemia in children	1028
7a. Describe the Sodium (Na) homeostasis in the body.....	1028
7b. Outline the management of a 10 kg weight boy with hyponatremic dehydration	1029
8a. National immunization schedule	1029
8b. Methods of disinfection.....	1030
9a. Malaria surveillance.....	1031

9b. Janani-Shishu Suraksha Karyakram (JSSK).....	1033
10a. Pathophysiology of diabetic ketoacidosis	1034
10b. Management of childhood diabetes	1035

DNB Pediatrics December 2021

1036

1a. Rotation of gut during embryonic development and applied aspects	1036
1b. Development of diaphragm with applied aspects	1036
2a. Brachial plexus with applied anatomy	1037
2b. Internal capsule with applied anatomy	1038
3a. Pulmonary function tests for asthma	1039
3b. Physiology of lactation.....	1039
4a. CSF circulation with Applied aspects.....	1039
4b. Hyperkalemia - ECG changes and management.....	1039
5a. Urea cycle disorders	1039
5b. Rehydration solution for malnourished children	1041
6a. Pathophysiology of dengue fever.....	1041
6b. Chronic constipation - Pathology	1041
7a. Pharmacokinetics of acetaminophen.....	1043
7b. Insulin analogues	1043
8a. Hodgkin's Lymphomas - Pathophysiology	1044
8b. Non-Accidental Injury	1044
9a. Rashtriya Bal Swasthya Karyakram	1044
9b. Child Adoption - DOI Guidelines	1044
10a. MR campaign in India.....	1044
10b. Screening Tests - Lead Time, Sensitivity, Specificity, Positive and Negative Predictive Values	1045

Paper—II

DNB Pediatrics October 2023

1047

1a. List the complications seen in infants of diabetic mothers	1047
1b. Describe their pathophysiology	1047
1c. Discuss clinical manifestations and management of infant of diabetic mother.....	1047
2a. Management of chronic kidney disease.....	1047
2b. Amniocentesis.....	1047
3a. Neonatal thrombocytopenia.....	1048
3b. Management of Hemophilia A.....	1048
4a. Transport of the critically ill newborn.....	1048
4b. Therapeutic hypothermia	1048
5a. Apnea of prematurity	1048
5b. Prevention of bronchopulmonary dysplasia.....	1050
6a. Pathophysiology of severe acute malnutrition	1050
6b. Refeeding syndrome.....	1051
7a. MR vaccine.....	1051
7b. Vitamin B1 deficiency	1051
8a. Alkaptonuria	1052
8b. Juvenile myelomonocytic leukemia (JMML).....	1052
9a. Acute disseminated encephalomyelitis.....	1053
9b. Diagnosis and treatment of steroid resistant nephrotic syndrome.....	1053
10a. Enumerate causes of acute flaccid paralysis (AFP).....	1053
10b. Define and classify migraine	1053

DNB Pediatrics April 2023

1054

1a. Role of newborn screening	1054
1b. Management of a neonate born to VDRL positive mother.....	1054
2a. Management of congenital hypothyroidism.....	1054
2b. Retinopathy of prematurity and its grading	1054
3a. Approach to anemia in a 2-year-old child.....	1054
3b. Treatment of iron deficiency anemia in children.....	1054
4a. Define global developmental delay	1055
4b. What are the screening tools for development delay?	1055
5a. How will you diagnose Autistic Spectrum Disorders (ASD)?	1055
5b. Name the interventions for ASD.....	1055
6a. Management of steroid resistant nephrotic syndrome (SRNS)	1055
6b. Dietary therapy in nephrotic syndrome	1055
7a. Management of a cyanotic spell	1055
7b. Fluid therapy in congestive cardiac failure	1055
8a. Role of CBC in evaluation of a child with fever.....	1055
8b. How to interpret indices in Coulter hemogram?	1056
9a. Enlist the criteria for diagnosis of SAM in <6 months old child.....	1056
9b. Role of ketogenic diet in the management of refractory epilepsy	1056
10a. Risk stratification of a newly diagnosed acute lymphatic leukemia.....	1056
10b. Management of tumour lysis syndrome	1056

DNB Pediatrics June 2022

1057

1a. Types of surfactants used in neonates.....	1057
1b. Lung protective strategy in neonatal ventilation.....	1057
2a. Approach to a neonate with disorder of sexual development.....	1058
2b. Hemorrhagic disease of newborn.....	1059
3a. Oral drugs in management of haemophilia	1059
3b. Complications of blood transfusion	1060
4a. Approach to a 2 years old boy with polyuria	1062
4b. Advances in management of steroid resistant nephrotic syndrome.....	1062
5a. Outline the management of a 2 years old conscious child with severe acute malnutrition having diarrhoea with severe dehydration	1063
5b. Dietary advice for a one year old child.....	1064
6a. Approach to a 6 years old boy with short stature	1064
6b. WHO growth charts.....	1065
7a. Diagnostic approach to a floppy infant	1065
7b. Acute Flaccid Paralysis surveillance.....	1065
8a. Neutrally adjusted ventilatory assist (NAVA)	1065
8b. Neurocutaneous markers.....	1066
9a. Enumerate oncological emergencies in newly diagnosed cases of acute leukemia	1066
9b. Write clinical features, management, and long-term outcome of B12 deficiency in children	1068
10a. Transport of a sick newborn.....	1068
10b. Probable complications in monozygotic twins.....	1069

DNB Pediatrics December 2021

1070

1a. Mission indradhanush.....	1070
1b. Types of adverse events Following immunization.....	1072
2a. Urinary tract infection in children—Imaging Guidelines	1072
2b. Renal biopsy—Indications.....	1073

3a. Neural tube defects—Early diagnosis and prevention	1073
3b. Childhood migraine	1073
4a. Immune thrombocytopenic purpura—Management Guidelines.....	1075
4b. Sickle cell crisis—Clinical presentation and management.....	1075
5a. Acute lymphoblastic leukemia—Cytogenetics and risk stratification.....	1075
5b. Bone marrow transplant—Indications and complications.....	1076
6a. Super ORS—Advantages over low osmolality ORS.....	1076
6b. Vitamin A deficiency—Classification and preventive measures.....	1076
7a. Neonatal HIV—Modalities of management	1077
7b. TORCH infections—Prevention.....	1077
8a. Management of premature baby in labour room.....	1077
8b. BFHI—Steps	1077
9a. Neonate of Rh negative mother—Management	1078
9b. Neonate born to COVID positive mother—Approach.....	1078
10a. Inhaled nitric oxide therapy—Therapeutics.....	1079
10b. Indications of ECMO.....	1079

Paper—III

DNB Pediatrics October 2023

1080

1a. Regulation of plasma osmolality	1080
1b. Definition, clinical manifestations and treatment of hyponatremia.....	1080
2a. Diagnosis of systemic lupus erythematosus.....	1081
2b. Define anion gap and causes of abnormal anion gap.....	1081
3a. Stevens-Johnson syndrome	1081
3b. Pathophysiology and treatment of salicylate poisoning in young children	1082
4a. Diagnosis and management of acute pancreatitis.....	1082
4b. Diagnosis and treatment of supraventricular tachycardia	1084
5a. Pathophysiology of shock.....	1084
5b. Management of septic shock	1084
6a. Management of acute hepatic failure	1084
6b. Management of attention deficit hyperactivity syndrome	1084
7a. Indications of genetic counselling.....	1084
7b. Diagnosis and treatment of severe combined immunodeficiency (SCID).....	1084
8a. Sexual Maturity Rating (SMR) stages in males.....	1084
8b. Intramuscular immunoglobulin	1084
9a. Pathogenesis and management of diphtheria	1085
9b. Chronic lymphocytic thyroiditis	1086
10a. Long term management of Type 1 diabetes mellitus (excluding DKA)	1088
10b. Treatment of acne vulgaris.....	1088

DNB Pediatrics April 2023

1089

1a. Karyotype in Down's syndrome and its role in genetic counselling.....	1089
1b. Principles of gene therapy	1089
2a. Differential diagnosis in a child with swelling of multiple joints for 6 weeks duration.....	1089
2b. Classification and diagnostic criteria of JIA	1089
3a. Sexual Maturity Rating in girls.....	1090
3b. Define precocious puberty and its causes	1090
4a. Approach to a suspected primary immunodeficiency disorder	1090
4b. Clinical features and laboratory findings in primary B cell immunodeficiency	1090

5a. Diagnosis of enteric fever.....	1090
5b. Management of septic shock	1090
6a. Outline the management of Patent Ductus Arteriosus (PDA)	1090
6b. How will you differentiate an innocent murmur from an organic cardiac murmur	1090
7a. Describe the physiological basis of gastroesophageal reflux.....	1090
7b. Discuss clinical features and management of GERD	1090
8a. Recent advances in insulin therapy.....	1091
8b. Clinical features of classical CAH	1092
9a. Discuss the differential diagnosis in a 6-year-old child with easy bruisability.....	1092
9b. Enumerate relevant investigation for each differential diagnosis	1093
10a. Outline management of dog bite in a 4-year-old child	1093
10b. Describe management of scorpion bite.....	1093

DNB Pediatrics June 2022

1094

1a. Severe combined immunodeficiency.....	1094
1b. <i>Autism spectrum disorder</i> : Early diagnosis and management	1095
2a. Classification of birth defects	1095
2b. Approach to a suspected case of inborn errors of metabolism	1096
3a. Pulse oximetry screening for critical congenital heart disease	1097
3b. Approach to manage a neonate with cyanotic congenital heart disease	1098
4a. <i>Arrhythmias in children</i> : Diagnosis and their immediate management in emergency room.....	1099
4b. Approach to a child brought to the emergency room with a history of road traffic accident (RTA)	1102
5a. Management of acetaminophen poisoning	1103
5b. Pulmonary function test in childhood Asthma.....	1103
6a. <i>Congenital hypothyroidism</i> : Etiology, diagnosis and management	1103
6b. Diagnosis and management of growth hormone deficiency.....	1103
7a. Describe the etiopathogenesis, clinical manifestation and management of portal hypertension in children.....	1103
7b. Define acute liver failure in children and how to manage it	1103
8a. Ophthalmia neonatorum	1106
8b. Hearing assessment screening in children	1106
9a. Bulimia nervosa	1106
9b. Anthelmintic drugs.....	1107
10a. Diagnostic evaluation of celiac disease	1108
10b. Haemophagocytic lymphohistiocytosis in children.....	1108

DNB Pediatrics December 2021

1111

1a. Fulminant hepatic failure in children—management.....	1111
1b. Bio-artificial liver.....	1113
2a. Upper GI bleed in children—etiology and management.....	1114
2b. Chronic granulomatous disease.....	1115
3a. Diabetic ketoacidosis—management.....	1117
3b. Management of cyanotic spell.....	1117
4a. Infective endocarditis—management and preventive prophylaxis	1117
4b. Kawasaki disease—classification of coronary involvement and management.....	1120
5a. Adolescent health needs and health problems.....	1120
5b. Unknown poisoning—approach in management	1120
6a. Ocular manifestations of systemic diseases	1123
6b. Audiological evaluation—indications and modalities.....	1124
7a. POCSO Act—guidelines in management	1125
7b. Nocturnal enuresis.....	1125
8a. Juvenile rheumatoid arthritis in children—classification and diagnosis	1125

8b. Primary immunodeficiency—management	1125
9a. Antenatal diagnosis of congenital malformations.....	1126
9b. Fetal therapy	1127
10a. MDR TB—diagnosis and management.....	1127
10b. Antitoxin therapy in diphtheria—guidelines	1127

Paper—IV

DNB Pediatrics October 2023

1128

1a. Coagulation Cascade.....	1128
1b. Thrombotic disorders in children.....	1128
2a. Enzyme replacement therapy	1129
2b. Gene therapy.....	1129
3a. Diagnostic testing for Mitochondrial disease.....	1129
3b. Molecular pathogenesis of Progeria	1129
4a. Management of Diabetic Ketoacidosis	1129
4b. Management of acute severe asthma	1129
5a. Biologic therapies in Juvenile Idiopathic Arthritis	1129
5b. Diagnosis and management of Juvenile Dermatomyositis.....	1129
6a. Etiopathogenesis of Hemolytic Uremic syndrome (HUS).....	1130
6b. Management of HUS	1130
7a. Tracheoesophageal fistula.....	1130
7b. Bronchoalveolar lavage	1130
8a. Classification of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutations.....	1131
8b. Newer drugs for Cystic fibrosis treatment.....	1132
9a. Clinical presentation and diagnosis of Ewing's sarcoma	1132
9b. Treatment of ventricular septal defect.....	1132
10a. Pathophysiology of sickle cell disease.....	1132
10b. Management of acute chest syndrome	1133

DNB Pediatrics April 2023

1134

1a. How will you manage a 2-year-old child presenting with status epilepticus?	1134
1b. Newer drugs in spinal muscular atrophy.....	1134
2a. Diagnostic criteria for rheumatic fever in children	1135
2b. Newer drugs in the treatment of cystic fibrosis.....	1135
3a. Recent advances in management of childhood asthma	1135
3b. Role of Zn, Cu and Mg in nutrition and disease	1135
4a. Pedigree chart and pattern of inheritance	1135
4b. Human milk banking.....	1137
5a. Role of oxygen free radicals in diseases.....	1137
5b. Indications of growth hormone replacement therapy.....	1138
6a. Explain the anatomical and functional factors for obstructive sleep apnea	1139
6b. How will you diagnose and treat OSA?	1140
7a. Components of Nutritional Rehabilitation Centres.....	1141
7b. Enumerate the differences between Hirschsprung disease and functional constipation.....	1141
8a. Hypothalamic pituitary axis	1142
8b. Passive immunity and its clinical application in pediatric disease.....	1144
9a. Indications of CSF manometry in children	1145
9b. Ventriculoperitoneal shunt in children	1145
10a. Molecular diagnostic parameters in the diagnosis of acute myeloid leukemia.....	1147
10b. Indications of Rituximab in pediatric diseases.....	1147

DNB Pediatrics June 2022

1148

1a. Fetal surgery	1148
1b. Vaccine hesitancy.....	1149
2a. Pattern of inheritance & diagnosis of mitochondrial diseases	1150
2b. Indication of next-generation sequencing in pediatric hematology-oncology	1150
3a. Antibiotic stewardship.....	1151
3b. Advances in management of Cystic Fibrosis.....	1151
4a. Liver transplantation in children	1152
4b. Volume targeted ventilation	1152
5a. Changes in American Heart Association Guidelines in 2020 for Pediatric Advanced Life Support	1153
5b. Functional renal imaging & renography.....	1154
6a. Updated definition of elevated Blood Pressure, Stage 1 and Stage 2 Hypertension in children.....	1155
6b. Discuss evaluation of a child with BP > 95th centile+12 mm Hg recorded twice during OPD visits	1155
7a. Rituximab.....	1155
7b. Describe Renal Anginal Index and its scoring	1156
8a. Antenatal diagnosis of Down Syndrome.....	1156
8b. Intrauterine transfusion	1156
9a. Extracorporeal Membrane Oxygenation (ECMO).....	1158
9b. Near Infra-Red Spectroscopy (NIRS)	1158
10a. Artificial Intelligence in medical science	1159
10b. Mission Neonatal Early Evaluation Vision.....	1160

DNB Pediatrics December 2021

1161

1a. Gastroesophageal Reflux Disease (GERD)—Management	1161
1b. Recent advances in management of Duchenne muscular dystrophy.....	1161
2a. Paediatric Covid—Classification and management.....	1162
2b. Malaria Vaccines	1164
3a. All possible radiologic and echocardiographic findings of Rheumatic heart disease	1165
3b. Fetal Surgical Therapy	1165
4a. Causes of metabolic acidosis and compensation by body.....	1165
4b. Recent advances in management of Haemophilia.....	1165
5a. Haemophagocytic Lymphohistiocytosis in children.....	1167
5b. Paediatric stroke—Management.....	1167
6a. End tidal CO ₂ measurement and interpretation.....	1167
6b. Attention deficit/hyperactivity disorder in children—Management.....	1168
7a. Congenital talipes equinovarus—Management	1168
7b. Mucopolysaccharidoses—Classification and clinical features	1170
8a. Dog bite in children—Guidelines in Management	1170
8b. Enzyme Replacement Therapy.....	1170
9a. Monoclonal antibody use in Paediatric practice	1170
9b. Plasmapheresis in children - Indications	1171
10a. Newborn Screening Tests and Interpretation.....	1172
10b. Temper tantrums in children—Presentation and management	1172

Other University Papers

1173

<i>Suggested Reading</i>	1205
<i>Index</i>	1213

Basic Sciences of Anatomy, Physiology Related to Genetics—I

Total duration: 3 hr

Total marks: 100

1. LAQ: Describe the development of fetal heart in details. Describe the transition from fetal to neonatal circulation. Add note on interventional cardiac catheterization57
2. LAQ: Discuss the physiology of hemostasis. Discuss the evaluation of child with bleeding/coagulation disorder ...59
3. SAQ: (any five out of six)
 - a. Gene therapy59
 - b. Hypokalemia61
 - c. Neural tube defect.....62
 - d. Clinical assessment of acid-base disorders65
 - e. Progeria.....66
 - f. Leukopenia.....68




1. Describe the development of fetal heart in details. Describe the transition from fetal to neonatal circulation. Add note on interventional cardiac catheterization.

Interventional Cardiac Catheterization

- Catheter treatment is the standard of practice for most cases of *isolated pulmonary or aortic valve stenosis as well as for recoarctation of the aorta*.
- A special catheter with a *sausage-shaped balloon* at the distal end is passed through the obstructed valve. Quick filling of the balloon with a mixture of contrast material and saline solution leads to tearing of the stenotic valve tissue, mostly at the site of inappropriately fused raphe.
- **Complication:** Creation of valvular insufficiency.
- **Balloon angioplasty** is the procedure of choice for cases with restenosis of coarctation of the aorta after earlier surgery.
- **Other applications** of the balloon angioplasty technique include:
 - Amelioration of mitral stenosis
 - Dilation of surgical conduits (e.g., RV-PA conduits)
 - Relief of branch pulmonary artery (PA) narrowing
 - Dilation of systemic or pulmonary venous obstructions
 - Long-used balloon atrial septostomy (Rashkind procedure) for transposition of the great arteries.
- Closure of a small *patent ductus arteriosus* (PDA) is routinely done with catheter-delivered coils, whereas a larger PDA can be closed with a variety of sandwich-type devices.
- Closure of *anomalous vascular connections* (coronary fistulas, venovenous collaterals in cyanotic heart lesions) can also be achieved using coils.
- *Secundum ASDs* can be closed with a double-disk occluder device.


- Interventional catheterization techniques are being adapted for use in the *fetus* with lesions, e.g., aortic stenosis to prevent their progression to more complex lesions, e.g., hypoplastic left heart syndrome (HLHS). In these procedures, after giving appropriate anesthesia, a needle is passed through the maternal abdominal wall, the uterine wall, and the fetal chest wall and directly into the fetal left ventricle. A coronary angioplasty balloon catheter is passed through the needle and across the stenotic aortic valve, which is then dilated. With the restoration of normal LV blood flow, normal LV growth potential is nearly restored.



Development of heart. Timeline formation of the heart.

2. Discuss the physiology of hemostasis. Discuss the evaluation of child with bleeding/coagulation disorder.

See MD Summer 2014 I 2 (Page 241)



Evaluation of a child with bleeding/coagulation disorder.



SAQ

3. Any five out of six.

a. Gene therapy.

Definition

- Gene therapy is the introduction of a gene sequence into a cell with the aim of modifying the cell's behavior in a clinically relevant fashion.
- It may be used in several ways, e.g., to correct a genetic mutation (as for cystic fibrosis), to kill a cell (as for cancer) or to modify susceptibility (as for coronary artery disease).
- The gene may be introduced using a virus (usually a retrovirus or adenovirus) or by means of lipid or receptor targeting.
- Gene delivery to somatic cell to treat disease is ethical, and gene therapy should take place alongside other forms of medical treatment.

Gene Therapy Process

- In gene therapy, a normal gene is inserted into the genome to replace an abnormal gene responsible for causing a certain disease.
- Stem cells targeted in various diseases include blood (adenosine deaminase deficiency), bone marrow (Fanconi anemia), respiratory epithelium (α 1-antitrypsin deficiency), tumor, liver (familial hypercholesterolemia), skin fibroblasts (hemophilia B), synovial membrane (rheumatoid arthritis), etc.

- A molecular carrier called a “*vector*” is used to release the gene, which needs to be:
 - Very specific
 - Display efficiency in the release of ≥ 1 genes of the sizes necessary for clinical applications
 - Not be recognized by the immune system
 - Be purified in large quantities and high concentrations so that it can be produced and made available on a large scale.
- Once the vector is inserted into the patient, it cannot induce allergic reactions or inflammatory process. It should:
 - Increase the normal functions
 - Correct deficiencies
 - Inhibit deleterious activities
 - Be safe not only for the patient, but also for the environment and for the professionals who manipulate it
 - Be capable to express the gene, in general, for the patient’s entire life.
- **Limitations:** The presence of viral genetic material in the plasmid can induce an acute immune response, besides a possible oncogenic transformation.
- There are two main *approaches for genetic modifications* of the cells:
 1. Virus-mediated (Retrovirus, Lentivirus, Herpes virus, Adenovirus, Plasmid)
 2. Via physical mechanisms, from preparations obtained by advanced nanotechnology techniques. There are polymers that form networks that capture a gene and release its load when they penetrate the cells, e.g., DNA micro-injections, cationic polymers, cationic liposomes, and particle bombardment.

Gene Therapy Protocols

- The specific body cells that require therapy are to be identified and accessible.
- A way to effectively distribute the gene copies to the cells should be available, and the disorders and their genetic bonds should be completely understood.
- The target cell type of gene therapy is subdivided into two large groups: Gene therapy of the germline and gene therapy of somatic cells.
- In germline gene therapy, the stem cells, e.g., with the sperm and egg, are modified by the introduction of functional genes, which are integrated into the genome. The modifications are hereditary and pass on to subsequent generations. Theoretically, this approach must be highly effective in the fight against genetic and hereditary conditions.
- Somatic cell gene therapy is when therapeutic genes are given to an individual’s somatic cells. Any modification and any effects are restricted only to that individual and are not inherited by future generations.

Disease	Objective
Adenosine deaminase deficiency	Substitution of the adenosine deaminase deficiency
$\alpha 1$ -antitrypsin deficiency	Substitution of $\alpha 1$ -antitrypsin
AIDS	Inactivation of the HIV-presenting Ag
Cancer	• Improvement of immune function • Tumor removal • Chemoprotection • Stem cell marking
Cystic fibrosis	Enzymatic substitution
Familial hypercholesterolemia	Substitution of low-density lipoprotein receptors
Fanconi anemia	Complement C gene release
Gaucher disease	Glucocerebrosidase substitution
Hemophilia B	Factor IX substitution
Rheumatoid arthritis	Cytokine release

Ethical issues: A large part of the scientific community approves genetic therapy in somatic cells, especially in cases of severe disorders, e.g., cystic fibrosis and Duchenne muscular dystrophy. Although, debate exists on various issues related to the misuse of gene therapy.

b. Hypokalemia.

Definition

It is defined as reduced serum K levels (i.e., <3.5 mEq/L).

Causes

- *Spurious:* High WBC count
- *Transcellular shifts:* Alkalemia, insulin, α -adrenergic agonists, drugs/toxins (theophylline, Ba, toluene, CsCl, hydroxychloroquine), hypokalemic periodic paralysis, thyrotoxic period paralysis, refeeding syndrome
- *Reduced intake:* Anorexia nervosa
- *Extrarenal losses:* Diarrhea, laxative abuse, sweating, Na polystyrene sulfonate (Kayexalate) or clay ingestion
- *Renal losses:*
 - *With metabolic acidosis:* Distal renal tubular acidosis (RTA), proximal renal tubular acidosis, uretero-sigmoidostomy, diabetic ketoacidosis
 - *Without specific acid-base disturbance:* Tubular toxins (amphotericin, cisplatin, aminoglycosides), interstitial nephritis, diuretic phase of acute tubular necrosis, postobstructive diuresis, hypomagnesemia, high urine anions (e.g., penicillin or penicillin derivatives)
 - *With metabolic alkalosis:*
 - ♦ *Low urine Cl^- :* Emesis or nasogastric suction, Cl^- -losing diarrhea, cystic fibrosis, low- Cl^- formula, posthypercapnia, previous loop or thiazide diuretic use
 - ♦ *High urine Cl^- and normal BP:* Gitelman syndrome, Bartter syndrome, AD hypoparathyroidism, loop and thiazide diuretics
 - ♦ *High urine Cl^- and high BP:* Adrenal adenoma or hyperplasia, glucocorticoid-remediable aldosteronism, renovascular disease, renin-secreting tumor, 17β -hydroxylase deficiency, 11β -hydroxylase deficiency, Cushing syndrome, 11β -hydroxysteroid dehydrogenase deficiency
 - *Liddle syndrome*

Clinical Features

- The heart and skeletal muscle are especially vulnerable to hypokalemia. ECG changes include a flattened T wave, a depressed ST segment, and the appearance of a U wave, which is located between the T wave (if still visible) and the P wave. Ventricular fibrillation and torsades de pointes may occur. Hypokalemia makes the heart especially susceptible to digitalis-induced arrhythmias, e.g., supraventricular tachycardia, ventricular tachycardia, and heart block.
- Muscle weakness and cramps may occur. Paralysis can occur if K levels <2.5 mEq/L. It mostly begins in the legs and involves the arms. Respiratory paralysis may need mechanical ventilation. Some patients have rhabdomyolysis; the risk rises with exercise.
- Hypokalemia reduces gastrointestinal motility, leading to constipation. At K levels <2.5 mEq/L, an ileus may occur.
- It affects bladder function, and may cause urinary retention.
- It causes polyuria and polydipsia by affecting urinary concentrating ability, which results in nephrogenic diabetes insipidus.
- It stimulates renal NH_3 production, an effect that is clinically significant if hepatic failure is present, as the liver cannot metabolize the NH_3 . Consequently, it may worsen hepatic encephalopathy.
- Chronic hypokalemia may lead to kidney damage, e.g., interstitial nephritis and renal cysts.

Diagnosis

- Child's diet, gastrointestinal losses, and medications history is taken.
- The presence of hypertension suggests excess mineralocorticoids. Concomitant electrolyte abnormalities are helpful clues.

- Hypokalemia with metabolic acidosis are mostly seen in diarrhea and distal and proximal RTA.
- A concurrent metabolic alkalosis is seen in emesis or nasogastric losses, aldosterone excess, use of diuretics, and Bartter and Gitelman syndromes.
- If a clear etiology is not apparent, the measurement of urinary K distinguishes between renal and extrarenal losses. The kidneys should conserve K in the presence of extrarenal losses. Urinary K losses can be assessed with a 24 hours urine collection, a spot K creatinine ratio, a fractional excretion of K, or calculation of the trans-tubular K gradient (TTKG):

$$TTKG = (\text{urine K/plasma K}) \times (\text{plasma osmolality/urine osmolality})$$

Urine osmolality must be more than serum osmolality for the result of this calculation to be valid. A TTKG >4 in the presence of hypokalemia suggests excessive urinary losses of K.

Treatment

- Factors affecting the treatment are the K level, clinical symptoms, renal function, the presence of transcellular shifts of K, ongoing losses, and the patient's ability to tolerate oral K.
- Severe, symptomatic hypokalemia needs aggressive treatment. Supplementation is more cautious if renal function is poor due to the kidney's limited ability to excrete excessive K.
- Serum K level does not always give an accurate estimation of the total body K deficit as there may be shifts of K from the intracellular space to the plasma. Clinically, such shifts occur most commonly with metabolic acidosis and the insulin deficiency of diabetic ketoacidosis; the serum K measurement underestimates the degree of total body K depletion. When these problems are corrected, K moves into the intracellular space, so more K supplementation is required to correct the hypokalemia. Likewise, the presence of a transcellular shift of K into the cells indicates that the total body K depletion is less severe. In an isolated transcellular shift, as occurs in hypokalemic periodic paralysis, K supplementation is used cautiously, given the risk of hyperkalemia when the transcellular shift resolves.
- Patients who have ongoing losses of K need correction of the deficit and replacement of the ongoing losses.
- Due to the risk of hyperkalemia, IV K should be used very cautiously. Oral K is safer, albeit not as rapid in urgent situations. Oral dose: 2–4 mEq/kg/day with a maximum of 120–240 mEq/day in divided doses; IV dose: 0.5–1.0 mEq/kg, usually given over 1 hour. The adult maximum dose is 40 mEq. Conservative dosing is generally preferred.
- KCl is the usual choice for supplementation, although the presence of concurrent electrolyte abnormalities should be considered. Patients with acidosis and hypokalemia can receive K acetate or K citrate. If hypophosphatemia is present, then some of the K deficit can be replaced with K phosphate.
- It is sometimes possible to reduce ongoing losses of K. For patients with excessive urinary losses, K-sparing diuretics are effective, but they should be used cautiously in patients with kidney disease.
- If hypokalemia, metabolic alkalosis, and volume depletion are present (with stomach losses), then restoration of intravascular volume with adequate NaCl will reduce urinary K losses. Correction of associated hypomagnesemia is essential as it may cause hypokalemia. Disease-specific therapy is effective in many of the genetic tubular disorders.

c. Neural tube defect.

Definition

CNS starts as a neural tube and folds into the brain and spinal cord by a complex mechanism during early embryologic development. Failure of normal closure results in neural tube defects (NTDs).

Types of NTDs

- **Primary NTDs:** They constitute the majority of NTDs and occur due to primary failure of closure of the neural tube or disruption of an already closed neural tube between 18 and 25 day' gestation. The resulting abnormality manifests in two anatomic lesions: an exposed (open or aperta) neural placode along the midline of the back caudally and rostrally and the Arnold-Chiari II malformation (malformation of pons and medulla, with downward displacement of cerebellum, medulla, and 4th ventricle into the upper cervical region), with associated aqueductal stenosis and hydrocephalus.

- *Myelomeningocele*: It is the most common primary NTD. A saccular outpouching of neural elements (neural placode), mostly through a defect in the bone and the soft tissues of the posterior thoracic, sacral, or lumbar (~80% cases) regions are seen. Arachnoid is typically included in the sac (meningo), which contains visible neural structures (myelo), and the skin is discontinuous over the sac. Hydrocephalus, Chiari II malformation and cerebral cortical dysplasia are also seen in these patients.
- *Encephalocele*: This defect of anterior neural tube closure is an outpouching of dura with or without brain, noted in the occipital region, and less commonly in the frontal, parietal, or temporal regions.
- *Anencephaly*: In this defect, the cranial vault and posterior occipital bone are defective, and derivatives of the neural tube are exposed, including both brain and bony tissue. It may extend through the foramen magnum and involve the brainstem. It is not compatible with long-term survival. Rachischisis is a more severe form wherein the spine is also involved due to nonfusion of the majority of the primary neural tube.
- *Secondary NTDs*: 5% of all NTDs result from abnormal development of the lower sacral or coccygeal segments during secondary neurulation. This leads to defects primarily in the lumbosacral spinal region. These heterogeneous lesions are rarely associated with hydrocephalus or the Chiari II malformation, and the skin is typically intact over the defect.
 - *Meningocele*: It is a spinal fluid-filled sac causing an outpouching of skin and dura without involvement of the neural elements aside from a commonly associated dorsal band of neurovascular tissue adherent to the sac. It may be associated with bone and contiguous soft tissue abnormalities.
 - *Lipomeningocele*: It is a lipomatous mass usually in the lumbar or sacral region, occasionally off the midline, typically covered with full-thickness skin. Adipose tissue frequently extends through the defect into the spine and dura and adheres extensively to a distorted spinal cord or nerve roots.
 - *Filum lipoma, sacral agenesis/dysgenesis, diastematomyelia, myelocystocele*, all may have varying degrees of bony involvement. As these lesions may be inapparent on physical examination of the child, the term *occulta* is used to describe them.

Etiology

Factors implicated include:

- Folic acid deficiency
- Maternal ingestion of the anticonvulsants carbamazepine and valproic acid and folic acid antagonists, e.g., aminopterin and certain antimalarial drugs
- Maternal diabetes
- Disruptive influences, e.g., antenatal irradiation and maternal hyperthermia
- Positive family history
- Genetic and chromosomal disorders such as trisomies 13 and 18, triploidy, and Meckel syndrome.

Prevention

- Women of childbearing age who are capable of becoming pregnant should consume 0.4 mg/day of folic acid to reduce their risks of having a fetus affected with NTDs.
- Higher doses (4 mg/day) beginning 1 month before conception to 12 (wkGA) are recommended for women with prior affected offspring.

Diagnosis

Antenatal diagnosis: The combination of maternal serum α -fetoprotein (AFP) determinations, antenatal USG, rapid acquisition fetal MRI scans, and AFP and acetylcholinesterase determinations on amniotic fluid where indicated, is useful to make antenatal diagnosis and to distinguish from abdominal wall defects.

- Maternal serum AFP measurements of 2.5 multiples of the median (MoM) in the 2nd trimester (16–18 wkGA) have a high sensitivity for myelomeningocele.
- Karyotype may also be done at the time of amniocentesis to detect associated chromosomal abnormalities.
- USG diagnosis through direct visualization of the spinal defect or through indirect signs related to Arnold-Chiari malformation can be done. The Chiari malformation is seen as a flattened cerebellum called a “banana

sign” and a transient frontal bone anomaly called a “lemon sign.” USG can also show the level of termination of the normal cord and placode.

- Antenatal MRI may define the defect more accurately.

Evaluation

- *History:* This includes:
 - Detailed family history about occurrence of NTDs and other congenital anomalies or malformation syndromes
 - Presence of risk factors.
- *Physical examination:*
 - *Back:* The defect is inspected and note is made if it is leaking CSF. A sterile nonlatex rubber glove is used when touching a leaking sac. The location, shape, and size of the defect and the thin “parchment-like” overlying skin, is noted. The sac may be deflated with a wrinkled appearance. The curvature of the spine and the presence of a bony gibbus underlying the defect is checked. For suspected closed lesions, presence of hemangioma, hairy patch, deep dimple, or sinus tract, if present, are documented; USG of the lower spine can show the level of the conus and presence of normal root movement.
 - *Head:* The head circumference is recorded and plotted daily until stable postoperatively. At birth, some infants will have macrocephaly due to hydrocephalus, and still, more will develop hydrocephalus after closure of the defect on the back. USG is useful to assess ventricular size. The intracranial pressure (ICP) is assessed with the baby sitting upright by palpating the anterior fontanel and tilting the head and torso forward until the midportion of the anterior fontanel is flat. The fontanels may be quite large and the calvarial bones widely separated.
 - *Eyes:* Abnormalities in conjugate movement of the eyes are common and include esotropias, esophorias, and CNVI paresis.
 - *Neurologic examination:* The child’s spontaneous activity and response to sensory stimuli in all limbs is observed.
 - *Lower limbs:* Deformities (e.g., clubfeet) as well as muscle weakness and limited range of motion are looked for. The thigh positions and skinfolds are examined and the Ortolani and Barlow maneuvers are done for evidence of congenital dysplasia of the hips. Dislocation of the hips can also be diagnosed by USG. Deep tendon reflexes are examined.
 - *Bladder and kidneys:* The abdomen is palpated for evidence of bladder distension or kidney enlargement. The pattern of urination is observed and the infant’s response to the Credé maneuver is checked to evaluate residual urine in the bladder.
 - *General neonate assessment:* All neonates with neural tube defects are evaluated for the presence of congenital heart disease (especially ventricular septal defect), renal malformation, and structural defects of the airway, gut, ribs, and hips. Other findings of associated chromosomal anomalies may be noted. An ophthalmologic examination and hearing evaluation is important.

Consultations

The care of an infant with a neural tube defect requires the coordinated efforts of a number of medical and surgical specialists, e.g., neurosurgery, neonatology, genetics, urology, orthopedics, physical therapy and social service.

Management

- *Fetal surgery:* In utero repair is associated with lower rates of ventriculoperitoneal (VP) shunting and consistent reversal of hindbrain herniation. Long-term effects remain uncertain. However, it is associated with high risk of complications during pregnancy including premature delivery and tearing of the uterine wall from the surgical scar.
- *Perinatal:* Cesarean section prior to the onset of labor is the preferred mode of delivery as it decreases the likelihood of rupturing the meningeal sac and is associated with improved neurologic outcome.

- **Preoperative management:**
 - **Care of placode:** The neonate is kept in the prone position with a sterile saline-moistened gauze sponge placed over the defect covered by plastic wrap to reduce bacterial contamination and tissue damage related to dehydration.
 - **Infectious disease:** IV antibiotics (Ampicillin and Gentamicin) are given to diminish the risk of meningitis, particularly due to group B streptococci.
 - **Fluids/Nutrition:** As insensible losses are minimized by covering the lesion with plastic wrap, standard maintenance fluids are generally appropriate.
 - **Urologic/Renal:** Clean intermittent catheterization is indicated to check postvoid residuals until urologic and renal function are assessed.
- **Surgical treatment:**
 - Infants whose defect is covered with skin and whose nervous system is therefore not at risk for bacterial contamination may undergo elective repair, typically within the 1st 6 months of life.
 - The initial neurosurgical treatment of an open meningo-myelocele includes closing the defect to prevent infection and reducing the raised ICP. The back should be closed within the 1st 24–48 hours of life if safely possible to reduce the risk of infection. If intracranial hypertension occurs, then ventricular puncture or continuous ventricular drainage are done.
 - If hydrocephalus is severe from birth, it can be treated at the same time as the back closure.
 - Endoscopic 3rd ventriculocisternostomy with choroid plexus cauterization (ETV-CPC) can be done.
- **Postoperative management:**
 - **Neurology:** Baby should be kept prone or side-lying until the wound heals. Head circumference should be measured daily, particularly in the baby who has not had shunt placement. MRI brain and spine should generally be done postoperatively.
 - **Nutrition:** Feeding difficulties are commonly associated with the Chiari II malformation. Growth and nutritional status should be watched closely as well as the baby's ability to suck and swallow.
 - **Urologic/Renal:** Monitoring for urine output and postvoid residue by USG is required.

Prognosis

- Most of the children with NTDs survive.
- Some children may have neurological complications (e.g., raised ICP, shunt infection, seizures, lower limb paralysis, developmental delay, learning disabilities, hearing/vision disturbances), urological complications (e.g., urinary bladder incontinence, urinary tract infection, growth retardation), orthopedic complications (e.g., lower limb contractures, kyphosis/scoliosis) and endocrinopathies (e.g., growth hormone deficiency).

d. Clinical assessment of acid–base disorders.

Appropriate compensation during simple acid–base disorders.

Disorder	Expected compensation
Metabolic acidosis	$\text{PCO}_2 = 1.5 \times [\text{HCO}_3^-] + 8 \pm 2$
Metabolic alkalosis	PCO_2 increases by 7 mm Hg for each 10 mEq/L increase in serum HCO_3^-
Respiratory acidosis	
Acute	HCO_3^- increases by 1 for each 10 mm Hg increase in PCO_2
Chronic	HCO_3^- increases by 3.5 for each 10 mm Hg increase in PCO_2
Respiratory alkalosis	
Acute	HCO_3^- falls by 2 for each 10 mm Hg decrease in PCO_2
Chronic	HCO_3^- falls by 4 for each 10 mm Hg decrease in PCO_2

Normal values of arterial blood gases.

pH	7.35–7.45
HCO_3^-	20–28 mEq/L
PCO_2	35–45 mm Hg

Three-step process for interpreting acid–base disturbances.

In step 1, determine whether the pH is low (acidemia) or high (alkalemia).

In step 2, establish an explanation for the acidemia or alkalemia.

In step 3, calculate the expected compensation and determine whether a mixed disturbance is present.

Step 1	Acidemia or alkalemia											
	Acidemia						Alkalemia					
Step 2	Low $[\text{HCO}_3^-]$			High pCO_2			High $[\text{HCO}_3^-]$			Low pCO_2		
	Metabolic acidosis			Respiratory acidosis			Metabolic alkalosis			Respiratory alkalosis		
Step 3	Low pCO_2	Expected pCO_2	High pCO_2	Low HCO_3^-	Expected HCO_3^-	High HCO_3^-	Low pCO_2	Expected pCO_2	High pCO_2	Low HCO_3^-	Expected HCO_3^-	High HCO_3^-
	Mixed meta-bolic acidosis and respira-tory alkalosis	Simple meta-bolic acidosis	Mixed meta-bolic acidosis and respira-tory acidosis	Mixed respira-tory acidosis and meta-bolic acidosis	Simple respira-tory acidosis	Mixed respira-tory acidosis and meta-bolic alkalosis	Mixed meta-bolic alkalosis and respira-tory alkalosis	Simple meta-bolic alkalosis	Mixed meta-bolic alkalosis and respira-tory acidosis	Mixed respira-tory alkalosis and meta-bolic acidosis	Simple respira-tory alkalosis	Mixed respira-tory alkalosis and meta-bolic alkalosis

e. Progeria.

Hutchinson-Gilford progeria syndrome (HGPS), or progeria, is a rare, fatal, autosomal dominant (AD) segmental premature aging disease.

Etiology

- **Incidence:** 1 in 4 million live births.
- There is no gender, ethnic, or regional bias.
- Progeria is almost always a sporadic AD disease.
- It is caused by a single-base mutation in the *LMNA* gene, which results in the production of a mutant lamin A protein called progerin. Lamin A is an intermediate filament inner nuclear membrane protein. It is found in most differentiated cells of the body.
- Without progerin-specific treatment, patients with progeria develop premature progressive atherosclerosis. They die of cardiac failure, mostly between ages 5–20 years. Progerin is found in high concentration in skin and the vascular wall of normal older individuals compared to younger individuals, suggesting a role in normal aging.

Clinical Features

Children develop the appearance of accelerated aging, but both clinical and biologic overlaps with aging are segmental, or partial. Physical appearance changes dramatically each year that they age.

- **Dermatologic changes:**
 - Skin findings are variable in severity and include areas of discoloration, stippled pigmentation, tightened areas that can restrict movement, and areas of the trunk or legs where small (1–2 cm), soft, bulging skin is present.

- Although usually born with normal hair presence, cranial hair is lost within the 1st few years, leaving soft, downy, sparse immature hair on the scalp, no eyebrows, and scant eyelashes.
- Nail dystrophy occurs later in life.
- *Failure to thrive:*
 - Apparently normal fetal and early postnatal development is seen. Abnormalities in growth and body composition are readily apparent during infancy.
 - Severe failure to thrive, generalized lipoatrophy, wasting of limbs, circumoral cyanosis, and prominent veins around the scalp, neck, and trunk are evident.
 - Weight is usually normal at birth, but gradually decreases to <3rd percentile despite adequate caloric intake.
 - Patients reach an average final height of ~1 m and weight of ~15 kg. Head circumference is normal. The weight deficit is more severe as compared to the height deficit. It is associated with the loss of subcutaneous fat. This results in the emaciated appearance characteristic of progeria.
 - Loss of subcutaneous fat leads to high sensitivity to cold temperatures and foot discomfort caused by lack of fat cushioning.
 - Overt diabetes is very unusual in progeria, but ~30–40% of children have insulin resistance.
- *Ocular abnormalities:*
 - Tightened skin and a paucity of subcutaneous fat around the eyes are seen.
 - Hyperopia and signs of ocular surface disease from nocturnal lagophthalmos and exposure keratopathy like corneal ulceration and scarring may be seen. Photophobia is present.
- *Craniofacial and dental phenotypes:*
 - Craniofacial disproportion, with micrognathia and retrognathia caused by mandibular hypoplasia is present.
 - Oral and dental manifestations, e.g., hypodontia, delayed tooth eruption, severe dental crowding, ogival palatal arch, ankyloglossia, presence of median sagittal palatal fissure, and generalized gingival recession may be present.
- *Bone and cartilaginous abnormalities:*
 - Development of bone structure and density shows skeletal dysplasia which is not due to malnutrition.
 - Due to the facial disproportion, narrow nasal bridge and retrognathia intubation is extremely difficult, and fiberoptic intubation is recommended.
 - Acroosteolysis of the distal phalanges, distal clavicular resorption, and thin, tapered ribs are early signs of progeria (as early as 3 months of age).
 - A pyriform chest structure and small clavicles may cause reducible glenohumeral joint instability.
 - Spine and bony pelvis growth are normal.
 - Dysplastic growth of the femoral head and neck axis result in coxa valgus (i.e., straightening of the femoral head-neck axis >125°) and coxa magna, where the diameter of the femoral head is disproportionately large for the acetabulum, resulting in hip instability.
 - Contractures in multiple joints (e.g., fingers, elbows, hips, knees, ankles) may be seen at birth and may progress with age due to changes in the laxity of the surrounding soft tissue structures (joint capsule, ligament, skin).
- *Hearing:* Low-tone conductive hearing loss is pervasive in progeria and indicative of a stiff tympanic membrane and/or deficits in the middle ear bony and ligamentous structures.
- *Cardiovascular disease:*
 - ~80% of progeria deaths are caused by heart failure, possibly precipitated by events, e.g., superimposed respiratory infection or surgical intervention.
 - Hypertension, angina, cardiomegaly, metabolic syndrome, and congestive heart failure are common end-stage events.
 - Cerebrovascular arteriopathy and stroke may occur.
- *Sexual development:* Females with progeria can develop Tanner stage II secondary sexual characteristics, including signs of early breast development and sparse pubic hair. They do not achieve Tanner stage III. More than 50% of females experience spontaneous menarche at a median age of 14 years.

- *Normally functioning systems:* Liver, kidney, thyroid, immune, gastrointestinal, and neurologic systems (other than stroke related) remain intact. IQ is normal, possibly due to downregulation of progerin expression in the brain by a brain-specific micro-RNA, miRNA-9.

Laboratory Findings

- Clinical suspicion should be followed by *LMNA* genetic sequence testing.
- Serum leptin is below detectable levels (>90% cases) and insulin resistance (60% cases).
- Platelet count is often moderately high.
- High-density lipoprotein (HDL) cholesterol and adiponectin concentrations decrease with increasing age to values significantly below normal.
- Otherwise, lipid panels, high-sensitivity CRP, blood chemistries, liver and kidney function tests, endocrine test, and coagulation tests are generally normal.

Differential Diagnosis

Wiedmann–Rautenstrauch syndrome, Werner syndrome, Cockayne syndrome, Rothmund–Thomson syndrome, restrictive dermopathy, and Nestor–Guillermo progeria syndrome.

Treatment and Prognosis

- Patients develop a severe premature form of atherosclerosis. Before death, cardiac decline with left-sided hypertrophy, valvular regurgitation, and pulmonary edema develop; neurovascular decline with transient ischemic attacks (TIAs), strokes, and sometimes seizures can result in significant morbidity. Death occurs generally between ages 5 and 20 years, with a median life span of 14.5 years, resulting from heart failure, sometimes with superimposed respiratory infection; from head injury or trauma, including subdural hematoma; and rarely from stroke or complications from anesthesia during surgery.
- Growth hormone (0.05 mg/kg/day SC) results in high rate of weight gain and overall size, but still well below that seen in normal children. Low-dose aspirin therapy is recommended at 2 mg/kg/day.
- *Under research:*
 - *Lonafarnib:* Farnesyl transferase inhibitor
 - Everolimus (mTOR inhibitor).

f. Leukopenia.

- *Leukopenia* is a WBC count 2 SDs below an age-appropriate mean (<9,100/mm³ in neonates, <6,000/mm³ in children 1 month to 2 years age, and <4,000/mm³ in children >2 years age).
- Evaluation requires a careful history, physical examination, and review of the CBC with differential.
- *Lymphopenia:*
 - It is a decline in total lymphocytes below the lower range of normal (1,000/mm³ in older children and 4,500/mm³ in infants).
 - Most often, it results transiently from viral (e.g., HIV), fungal, or parasitic infections.
 - If lymphopenia persists, multiple cell lines are deficient, or common transiently acquired etiologies are not found, Ig measurements, flow cytometry, and CD4 and CD8 T-lymphocyte subset quantification are warranted.
- *Neutropenia:*
 - It is “mild” when the absolute neutrophil count (ANC) are 1,000–1500/mm³, “moderate” if 500–1,000/mm³, and “severe” (with high risk for a life threatening infection) if <500/mm³.
 - Evaluation of neutropenia in children involves a tiered approach including serial neutrophil counts, peripheral blood smear, withdrawal of a potential inciting medication, further laboratory testing (kidney and liver function tests, electrolytes, CRP, blood pH, Ig, screening for autoimmune or infectious etiologies), or bone marrow examination.
 - Patients are at high risk for *infectious complications*.
 - ♦ Most infections result from organisms that are normal flora (gram negative bacteria, *Candida albicans*, varicella, and *Pneumocystis*).

- ♦ Other exogenously acquired agents are *Pseudomonas* or *Aspergillus* species. *E. coli*, *Pseudomonas*, and *Klebsiella* species are the most common gram-negative organisms infecting immunocompromised children. Coagulase-negative staphylococci are the predominant gram-positive organisms that cause infection, especially in patients with central venous catheters (CVCs).
- ♦ Anaerobic infections are uncommon.
- ♦ *Candida* and *Aspergillus* species are the most common fungal infections.
- ♦ Most common viruses are HSV, VZV, CMV, EBV, and adenovirus. *Pneumocystis* and *Toxoplasma* represent the major protozoan infections in this group.
- ♦ The standard approach for neutropenic patients with fever and no focus of infection is combination therapy to cover gram-positive and gram-negative bacteria.
- ♦ Ceftazidime (or Piperacillin/Tazobactam) and Vancomycin are used as initial therapy (especially in patients with a CVC).
- ♦ Children with pneumonia or perirectal infections may require antibiotics that cover pathogens, e.g., *Pneumocystis* and *Clostridium*.
- ♦ Culturing from all central-line ports, as well as percutaneously ("peripheral blood culture") is useful. Additional tests include a CBC with differential, urine analysis with Gram stain and culture, and X-ray chest.
- ♦ A tracheal aspirate with a culture should be considered in patients who are tracheally intubated.
- ♦ Most simple catheter infections can be cleared with antibiotics without catheter removal. Despite appropriate antibiotics, many catheters must be removed to clear the infection.
- Treatment to stimulate neutrophil recovery should be considered. Recombinant human granulocyte colony-stimulating factor (rhGCSF or GCSF) (5–10 µg/kg SC) stimulates the production of neutrophils from committed progenitor cells in the marrow, and is often used for chemotherapy-related neutropenia. An improvement is generally noted in 10–14 day to an ANC >1,500/mm³.
- *Autoimmune neutropenia*:
 - ♦ It is caused by the production of Ab against neutrophil Ag.
 - ♦ This entity is usually self-limited, with recovery over several months.
 - ♦ Appropriate antibiotics should be given to febrile, neutropenic patients, as noted previously.
 - ♦ Treatment with rhGCSF is usually reserved for active bacterial infections or for prophylaxis against recurrent infections. Alternative treatments with steroids (Prednisone, 1–2 mg/kg/day for 1 week) and IVIg (a single dose of 1 g/kg) hasten recovery of the ANC.
- *Severe congenital neutropenia (SCN)*:
 - ♦ It is severe neutropenia (ANC <200/mm³) from birth.
 - ♦ Omphalitis, recurrent cellulitis, and abscesses are common.
 - ♦ SCN is most commonly secondary to heterozygous mutations in the elastase-neutrophil expressed (ELANE) gene.
- *Congenital cyclical neutropenia*:
 - ♦ It is caused by a defect in stem cell development, with ELANE gene mutations in 80–100%.
 - ♦ The duration of each cycle is ~21 day.
 - ♦ The most common manifestations are oral ulcers, stomatitis, pharyngitis, tonsillitis, lymphadenitis, cellulitis, otitis media, and sinusitis.
 - ♦ Presentation usually occurs in early childhood.
 - ♦ Infectious episodes should be treated with appropriate antibiotics and rhGCSF (5 µg/kg daily SC until the WBC count is ≥10,000/mm³).

Solved Papers **PEDIATRICS** *for PG Students*

This book is an effort to help pediatric students have an easy access to the answers to questions asked in previous years' MD (Pediatrics), DCH examinations, and DNB (Pediatrics). It will be useful for MD (Pediatrics), DCH, CPS, MBBS, NEET PG aspirants, NEET SS aspirants, and practicing pediatricians. This edition includes flowcharts, images, recent advances, and newer updates.

Ankit Yadavendra MBBS MD (Pediatrics) (BHIMS, Mumbai) has completed his MBBS from Dr Vaishampayan Memorial Government Medical College, Solapur, Maharashtra, India, with an excellent academic record. He has also completed MD (Pediatrics) from Bombay Hospital, Institute of Medical Sciences, Mumbai. He has worked as a Pediatric Resident at Lokmanya Tilak Municipal Medical College, Sion, Mumbai; as a Registrar at Manohar Waman Desai Municipal Hospital, Malad, Mumbai; as a Clinical Assistant at Dr LH Hiranandani Hospital, Mumbai; as a Consultant at Baltaru Child Clinic, Mumbai; and as a Consultant at Baby Care Child Clinic, Kushinagar, Uttar Pradesh. Currently, he is working at Krishna Advanced Paediatric Care Centre, Kushinagar. He has published *45 Notes to PG* book for PG aspirants. He has published *Solved Papers ObGy: NEONATOLOGY Questions*. He has a medical education channel on *YouTube*. He has MCQ discussion groups on *Telegram*.

Printed in India



Available at all medical bookstores
or buy online at www.ejaypee.com



JAYPEE BROTHERS
Medical Publishers (P) Ltd.
EMCA House, 23/23-B, Ansari Road,
Daryaganj, New Delhi - 110 002, INDIA
www.jaypeebrothers.com

Join us on [facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)
Follow us on [instagram.com/JaypeeMedicalPublishers](https://www.instagram.com/JaypeeMedicalPublishers)

Shelving Recommendation
PEDIATRICS

ISBN 978-93-6616-030-6

